Marvell Technology (MRVL) 424B3Prospectus supplement

Filed Pursuant to Rule 424(b)(3)
Registration File No. 333-259149

CONSENT SOLICITATION STATEMENT OF INNOVIUM, INC. AND PROSPECTUS OF MARVELL TECHNOLOGY, INC.

To Stockholders of Innovium, Inc.:

As you may be aware, Innovium, Inc. (“Innovium”) entered into an Agreement and Plan of Merger, dated as of August 2, 2021 (the “merger agreement”), with Marvell Technology, Inc. (“Marvell”), one of Marvell’s wholly owned subsidiaries and Shareholder Representative Services LLC, pursuant to which, through a merger, Innovium will become a wholly owned subsidiary of Marvell (the “merger”). The transactions contemplated by the merger agreement, including the merger, are collectively referred to as the “transaction.”

The aggregate consideration to be paid by Marvell will be approximately $1.1 billion, subject to certain adjustments set forth in the merger agreement, consisting of shares of Marvell common stock, based on a fixed price of $57.7409 per share, which represents the volume weighted average closing sale price per share of Marvell common stock on the Nasdaq Global Select Market (“Nasdaq”) for the 10 trading days ending on and including July 30, 2021, the trading day immediately preceding the date of the merger agreement. Subject to the applicable provisions of the merger agreement, each share of Innovium common stock, Innovium Series A preferred stock, Innovium Series B preferred stock, Innovium Series C preferred stock, Innovium Series D preferred stock, Innovium Series D2 preferred stock, Innovium Series E preferred stock and Innovium Series F preferred stock, in each case issued and outstanding immediately prior to the effective time (other than any cancelled shares or dissenting shares as described in the accompanying consent solicitation/prospectus), will automatically be cancelled and converted into the right to receive a number of shares of Marvell common stock equal to (i) in the case of Innovium Series E preferred stock and Innovium Series F preferred stock, the number of shares of Marvell common stock allocable from the aggregate merger consideration to each such share of Innovium preferred stock in accordance with the Innovium certificate based on the liquidation preference of such series of preferred stock, and (ii) in the case of the Innovium common stock, Innovium Series A preferred stock, Innovium Series B preferred stock, Innovium Series C preferred stock, Innovium Series D preferred stock and Innovium Series D2 preferred stock, a number of shares of Marvell common stock based on the quotient obtained by dividing (a)(i) the aggregate merger consideration of approximately $1.1 billion (subject to certain adjustments set forth in the merger agreement) minus (ii) the aggregate merger consideration allocable to the Innovium Series E preferred stock and Innovium Series F preferred stock, by (b) the number of shares of Innovium common stock outstanding on a fully diluted basis (excluding shares of common stock issuable upon conversion of then-outstanding shares of Innovium Series E preferred stock and Innovium Series F preferred stock) as calculated in accordance with the merger agreement. In all cases, the number of shares of Marvell common stock issuable will be determined based on the Marvell VWAP (as defined below) of $57.7409. As of September 17, 2021, the most recent practicable date prior to the printing of the accompanying consent solicitation/prospectus, based upon the number of shares of Innovium capital stock, options, RSUs (as defined below) and warrants outstanding and the estimated transaction expenses of Innovium, in each case determined in accordance with the merger agreement, and assuming the cancellation of certain performance-based restricted stock units which are expected to be cancelled immediately prior to the closing, and the continued employment by Marvell of all but certain specified Innovium employees after closing, each share of Innovium common stock, Innovium Series A preferred stock, Innovium Series B preferred stock, Innovium Series C preferred stock, Innovium Series D preferred stock and Innovium Series D2 preferred stock would be converted into approximately 0.1440 shares of Marvell common stock, each share of Innovium Series E Preferred Stock would be converted into approximately 0.1470 shares of Marvell common stock and each share of Innovium Series F Preferred Stock would be converted into approximately 0.1755 shares of Marvell common stock. Because Marvell’s share price and Innovium’s fully diluted share count may fluctuate between now and the completion of the transaction, and because the consideration will not be adjusted to reflect such changes in Marvell’s share price or Innovium’s fully diluted share count, Innovium stockholders cannot be sure of the value of the shares of Marvell common stock they will receive in the transaction, and the value of the Marvell common stock received by Innovium stockholders in the transaction may differ from the implied value based on the share price on the date of the merger agreement. See the section entitled “The Transaction—Consideration to Innovium Securityholders” in the accompanying consent solicitation/prospectus, including the hypothetical example set forth therein.

Marvell common stock is traded on Nasdaq under the symbol “MRVL.” On September 17, 2021, the most recent practicable date prior to the date of the accompanying consent solicitation/prospectus, the last reported sale price of Marvell common stock on Nasdaq was $62.10.

The board of directors of Innovium (the “Innovium board”) has considered the transaction and the terms of the merger agreement and has unanimously approved and declared advisable the merger agreement and the transaction, upon the terms and conditions set forth in the merger agreement, and unanimously determined that the merger agreement and the transaction are fair to and in the best interests of Innovium and its stockholders. The adoption of the merger agreement requires the affirmative vote or consent of (i) the holders of at least a majority of the outstanding shares of Innovium common stock and Innovium preferred stock (voting as a single class and on an as-converted basis) entitled to vote thereon and (ii) the holders of at least a majority of the outstanding shares of Innovium preferred stock (voting as a single class and on an as-converted basis) entitled to vote thereon (the foregoing clauses (i) and (ii), collectively, the “Innovium stockholder approval”).

The Innovium stockholder approval is required for the transaction to close, and you are being sent this document to ask you to approve the adoption of the merger agreement by executing and returning the written consent furnished with the accompanying consent solicitation/prospectus.

The Innovium board has set August 1, 2021 as the record date (the “record date”) for determining Innovium stockholders entitled to execute and deliver written consents with respect to this solicitation. If you are a holder of Innovium capital stock on the record date, you are urged to complete, date and sign the enclosed written consent and promptly return it to Innovium. See the section entitled “Solicitation of Written Consents” in the accompanying consent solicitation/prospectus.

Concurrently with the execution of the merger agreement, Marvell and certain stockholders of Innovium, representing approximately 65.09% of the outstanding shares of Innovium capital stock and approximately 71.98% of the outstanding shares of Innovium preferred stock as of the date of the merger agreement entered into a support agreement (the “support agreement”) under which they have agreed, promptly (and in any event within one business day) after the registration statement of which the accompanying consent solicitation/prospectus forms a part is declared effective by the Securities and Exchange Commission (the “SEC”), to execute and deliver written consents approving the adoption of the merger agreement and related matters with respect to all of their shares of Innovium capital stock entitled to act by written consent with respect thereto. The execution and delivery of written consents by all parties to the support agreement will constitute the Innovium stockholder approval and, therefore, we expect to receive a number of written consents sufficient to satisfy such approval.

No vote of Marvell stockholders is required to complete the transaction.

We encourage you to read carefully the accompanying consent solicitation/prospectus and the documents incorporated by reference into the accompanying consent solicitation/prospectus in their entirety, including the section entitled “Risk Factors” in the accompanying consent solicitation/prospectus.

Neither the SEC nor any state securities commission has approved or disapproved of the securities to be issued under the accompanying consent solicitation/prospectus, or determined if the accompanying consent solicitation/prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The accompanying consent solicitation/prospectus is dated September 20, 2021, and is first being delivered to Innovium stockholders on or about September 20, 2021.

Innovium, Inc.

6001 America Center Drive, Suite 200

San Jose, CA 95002

Notice of Solicitation of Written Consent

To Stockholders of Innovium, Inc.:

Pursuant to an Agreement and Plan of Merger, dated as of August 2, 2021 (the “merger agreement”), by and among Marvell Technology, Inc. (“Marvell”), a wholly owned subsidiary of Marvell (“Merger Sub”), Innovium, Inc. (“Innovium”) and Shareholder Representative Services LLC (the “Stockholder Representative”), Merger Sub will be merged with and into Innovium (the “merger”), with Innovium continuing as the surviving corporation and a wholly owned subsidiary of Marvell. The transactions contemplated by the merger agreement, including the merger, are collectively referred to as the “transaction.”

The accompanying consent solicitation/prospectus is being delivered to you on behalf of the board of directors of Innovium (the “Innovium board”) to request that Innovium stockholders as of the record date of August 1, 2021 approve the adoption of the merger agreement by executing and returning the written consent furnished with the accompanying consent solicitation/prospectus.

The accompanying consent solicitation/prospectus describes the merger agreement, the transaction and the actions to be taken in connection with the transaction and provides additional information about the parties involved. Please give this information your careful attention. A copy of the merger agreement is attached as Annex A to the accompanying consent solicitation/prospectus.

A summary of the appraisal rights that may be available to you is described in “Appraisal Rights” in the accompanying consent solicitation/prospectus. Please note that if you wish to exercise appraisal rights you must not sign and return a written consent approving the adoption of the merger agreement. However, so long as you do not return a written consent at all, it is not necessary to affirmatively vote against or disapprove the adoption of the merger agreement in order to exercise your appraisal rights. In addition, you must take all other steps necessary to perfect your appraisal rights.

The Innovium board has considered the transaction and the terms of the merger agreement and unanimously approved and declared advisable the merger agreement and the transaction, upon the terms and conditions set forth in the merger agreement, and unanimously determined that the merger agreement and the transaction are fair to and in the best interests of Innovium and its stockholders.

Please complete, date and sign the written consent furnished with the accompanying consent solicitation/prospectus and return it promptly to Innovium by one of the means described in “Solicitation of Written Consents” in the accompanying consent solicitation/prospectus.

By Order of the Board of Directors:

/s/ Lip-Bu Tan

Lip-Bu Tan

Director

TABLE OF CONTENTS

i

ii

IMPORTANT NOTE ABOUT THIS CONSENT SOLICITATION/PROSPECTUS

This consent solicitation/prospectus, which forms part of a registration statement on Form S-4 filed with the Securities and Exchange Commission (the “SEC”) by Marvell (File No. 333-259149), constitutes a prospectus of Marvell under Section 5 of the Securities Act of 1933, as amended (the “Securities Act”), with respect to the Marvell common stock to be issued to Innovium stockholders pursuant to the merger agreement.

Neither Marvell nor Innovium has authorized anyone to give any information or make any representation about the transaction, Marvell or Innovium that is different from, or in addition to, that contained in this consent solicitation/prospectus or in any of the materials that have been incorporated by reference. Therefore, neither Marvell nor Innovium takes any responsibility for, nor can provide any assurance as to the reliability of, any information other than the information contained in or incorporated by reference into this consent solicitation/prospectus.

This consent solicitation/prospectus is dated September 20, 2021. The information contained in this consent solicitation/prospectus is accurate only as of that date or, in the case of information in a document incorporated by reference, as of the date of such document, unless the information specifically indicates that another date applies. Neither the delivery of this consent solicitation/prospectus to Innovium stockholders nor the issuance by Marvell of common stock pursuant to the merger agreement will create any implication to the contrary.

This consent solicitation/prospectus does not constitute an offer to sell, or the solicitation of an offer to buy, any securities, in any jurisdiction in which or from any person to whom it is unlawful to make any such offer or solicitation in such jurisdiction.

The information concerning Marvell contained in or incorporated by reference into this consent solicitation/prospectus has been provided by Marvell, and the information concerning Innovium contained in this consent solicitation/prospectus has been provided by Innovium.

Unless otherwise indicated or as the context otherwise requires, all references in this consent solicitation/prospectus to:

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

RISK FACTORS

In reviewing the transaction described in this consent solicitation/prospectus, you should consider carefully the following risk factors, together with general investment risks and all of the other information included in, or incorporated by reference into, this consent solicitation/prospectus. This consent solicitation/prospectus also contains forward-looking statements that involve risks and uncertainties. Please read the section entitled “Special Note Regarding Forward-Looking Statements.”

The risks described below are certain material risks, although not the only risks, relating to the transaction and each of Marvell, Innovium and the surviving company in relation to the transaction. The risks described below are not the only risks that Marvell or Innovium currently faces or that Marvell or the surviving company will face after the completion of the transaction. Additional risks and uncertainties not currently known or that are currently expected to be immaterial may also materially and adversely affect the business, financial condition and results of operations of Marvell or the surviving company or the market price of Marvell common stock following the completion of the transaction.

If any of the following risks and uncertainties develop into actual events, these events could have a material adverse effect on the business, financial condition and results of operations of Marvell, Innovium and/or the surviving company. In addition, past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods.

Risks Related to the Merger

The number of shares of Marvell common stock that Innovium securityholders will receive under the merger agreement is based on a fixed value of a share of Marvell common stock determined as of the date of the merger agreement. The market value of the shares of Marvell common stock to be issued upon completion of the merger is unknown, and therefore, Innovium securityholders cannot be certain of the value of the shares of Marvell common stock to be issued in the merger.

Upon completion of the merger, shares of Innovium capital stock will be converted into the right to receive a number of shares of Marvell common stock based on a value per Marvell share of $57.7409, which was the volume weighted average price of a share of Marvell common stock for the ten trading day period up to and including the trading day immediately preceding the date of the merger agreement. The market value of a share of Marvell common stock at the time of the completion of the merger may vary significantly from its price on the date of the merger agreement, the date of this consent solicitation/prospectus or the date on which the Innovium stockholder consent is received. Because the Marvell VWAP will not be adjusted to reflect any changes in the market price of shares of Marvell common stock, the market value of the shares of Marvell common stock issued in the merger may be higher or lower than the value of such shares on earlier dates. Share price changes may result from numerous factors, including changes in the respective business operations and prospects of Marvell, changes in general market and economic conditions and regulatory considerations. Many of these factors are beyond the control of Marvell or Innovium. At the time at which the Innovium stockholder consent is solicited, Innovium stockholders will not know or be able to determine the value of the shares of Marvell common stock that such stockholders will receive pursuant to the merger agreement.

The market price of shares of Marvell common stock after the merger might be affected by factors different from, or in addition to, those currently affecting the market price of shares of Marvell common stock and the value of shares of Innovium capital stock.

The businesses of Marvell and Innovium differ and, accordingly, the results of operations of Marvell and the market price of shares of Marvell common stock after completion of the merger may be affected by factors different from, or in addition to, those currently affecting the independent results of operations of each of Marvell and Innovium. For a discussion of the business of Marvell and of factors to consider in connection with its

20

business, see the documents incorporated by reference into this consent solicitation/prospectus and referred to under “Where You Can Find More Information.”

There has been no public market for Innovium capital stock and the lack of a public market may make it more difficult to determine the fair market value of Innovium than if there were such a public market.

The outstanding shares of Innovium capital stock are privately held and are not traded on any public market. The lack of a public market may make it more difficult to determine the fair market value of Innovium than if the outstanding shares of Innovium capital stock were traded publicly. The value ascribed to Innovium’s securities in other contexts, including in private valuations or financings, may not be indicative of the price at which the outstanding shares of Innovium capital stock may have traded on a public market. The consideration to be paid to Innovium securityholders in the merger was determined based on negotiations between the parties and likewise may not be indicative of the price at which the outstanding shares of Innovium capital stock may have traded on a public market.

Until the completion of the merger or the termination of the merger agreement in accordance with its terms, Innovium is prohibited from entering into certain transactions and taking certain actions that might otherwise be beneficial to Innovium and its stockholders. Innovium is also restricted in its ability to pursue alternatives to the merger.

Until the merger is completed or the merger agreement is terminated, the merger agreement restricts Innovium from taking specified actions without the consent of Marvell, and requires Innovium to conduct its business and operations in the ordinary course of business. These restrictions may prevent Innovium from making appropriate changes to its businesses or pursuing attractive business opportunities that may arise prior to the completion of the merger. See “The Merger Agreement—Covenants and Agreements—Conduct of Business of Innovium Prior to Completion of the Transaction” for a description of the restrictive covenants applicable to Innovium.

The merger agreement contains non-solicitation provisions that restrict the ability of Innovium to (a) solicit, initiate, consider, knowingly encourage or accept any proposal or offer than constitutes an acquisition proposal or (b) participate in any discussions, conversations, negotiations or other communications regarding, or furnish to any other person any information with respect to, or otherwise knowingly cooperate in any way, knowingly assist or participate in, knowingly facilitate or encourage the submission of, any proposal that constitutes, or could reasonably be expected to lead to, an acquisition proposal (as defined under “The Merger Agreement—Covenants and Agreements—No Solicitation by Innovium”) for purposes of the merger agreement. In addition, the merger agreement does not permit Innovium to terminate the merger agreement in order to enter into an agreement providing for, or to complete, such an alternative transaction, even if the alternative transaction provides for the payment of consideration with a higher value per share of Innovium capital stock than the market value of Marvell common stock proposed to be received or realized in the transaction. See the section entitled “The Merger Agreement—Covenants and Agreements—No Solicitation by Innovium.”

The merger is subject to a number of conditions, some of which are outside of the parties’ control, and if these conditions are not satisfied or waived, the merger will not be completed.

The merger agreement contains a number of conditions that must be satisfied (or waived) prior to completion of the merger. Those conditions include, among other conditions:

21

The required satisfaction or waiver of the foregoing conditions could delay the completion of the merger for a significant period of time or prevent it from occurring at all. Any delay in completing the merger could cause the parties not to realize some or all of the benefits that the parties expect to achieve following the completion of the merger. Further, there can be no assurance that the conditions to the completion of the merger will be satisfied or waived or that the merger will be completed.

In addition, if the merger is not completed by May 2, 2022, either Marvell or Innovium may choose to terminate the merger agreement. Marvell or Innovium may also elect to terminate the merger agreement in certain other circumstances, or they may mutually decide to terminate the merger agreement at any time prior to the effective time, before or after obtaining stockholder approval. See “The Merger Agreement—Termination of the Merger Agreement” for a more detailed description of these circumstances.

The COVID-19 pandemic may delay or prevent the completion of the merger.

Given the ongoing and dynamic nature of the COVID-19 crisis, it is difficult to predict the impact of that crisis on the businesses of Marvell and Innovium, and there is no guarantee that efforts by Marvell or Innovium to address the adverse impact of the COVID-19 pandemic will be effective. If either Marvell or Innovium is unable to recover from a business disruption on a timely basis, Marvell’s business and financial condition and results of operations following the completion of the merger could be adversely affected. The merger may also be delayed or adversely affected by the COVID-19 pandemic, or become more costly due to Marvell policies, Innovium policies or government policies and actions to protect the health and safety of individuals, or government policies or actions to maintain the functioning of national or global economies and markets could delay or prevent the completion of the merger. Marvell or Innovium may also incur additional costs to remedy damages caused by such disruptions, which could adversely affect Marvell’s or Innovium’s financial condition or results of operations.

The business relationships of Marvell and Innovium and their respective subsidiaries may be subject to disruption due to uncertainty associated with the merger, which could have an adverse effect on the results of operations, cash flows and financial position of Marvell, Innovium and, following the completion of the merger, Marvell.

Parties with which Marvell and Innovium do business may experience uncertainty associated with the merger, including with respect to current or future business relationships with Innovium or Marvell. Marvell’s and

22

Innovium’s relationships may be subject to disruption as customers, suppliers and other persons with whom Marvell and Innovium have business relationships may delay or defer certain business decisions or might decide to seek to terminate, change or renegotiate their relationships with Marvell or Innovium, as applicable, or consider entering into business relationships with parties other than Innovium or Marvell. These disruptions could have an adverse effect on the results of operations, cash flows and financial position of Marvell, Innovium and, following the completion of the merger, Marvell, including an adverse effect on Marvell’s ability to realize the expected synergies and other benefits of the merger. The risk, and adverse effect, of any disruption could be exacerbated by a delay in completion of the merger or termination of the merger agreement.

Certain stockholders of Innovium have executed a support agreement that requires each such stockholder to deliver a written consent in favor of the adoption of the merger agreement, which will constitute approval of the transaction by Innovium stockholders, even if the Innovium board changes its recommendation.

Concurrently with the execution of the merger agreement, certain stockholders of Innovium entered into a support agreement with Marvell, pursuant to which each of the support stockholders has agreed, promptly (and in any event within two business days) after the registration statement of which this consent solicitation/prospectus forms a part is declared effective under the Securities Act by the SEC, to execute and deliver a written consent approving the adoption of the merger agreement and related matters with respect to all of their shares of Innovium capital stock entitled to act by written consent with respect thereto. The support stockholders are required to deliver such written consents even if the Innovium board changes its recommendation that Innovium stockholders approve the merger agreement proposal. The execution and delivery of written consents by all of the support stockholders will constitute the Innovium stockholder approval and, therefore, we expect to receive a number of written consents sufficient to satisfy such approval.

Risks Related to the Combined Company

Marvell may fail to realize the benefits expected from the merger, which could adversely affect Marvell’s share price.

The anticipated benefits Marvell expects from the merger are, necessarily, based on projections and assumptions about the combined businesses of Marvell and Innovium, which may not materialize as expected or which may prove to be inaccurate. The value of shares of Marvell common stock following the completion of the merger could be adversely affected if Marvell is unable to realize the anticipated benefits from the merger on a timely basis or at all. Achieving the benefits of the merger will depend, in part, on the successful and efficient integration of the operations of Innovium and Marvell. The challenges involved in this integration, which will be complex and time-consuming, include the following:

23

If Marvell does not successfully manage these issues and the other challenges inherent in integrating businesses of the size and complexity of Marvell and Innovium, then Marvell may not achieve the anticipated benefits of the merger on a timely basis or at all and Marvell’s revenue, expenses, operating results and financial condition could be materially and adversely affected.

Completion of the transaction may trigger change in control, assignment or other provisions in certain agreements to which Innovium is a party, which may have an adverse impact on the surviving company’s business and results of operations.

The completion of the transaction may trigger change in control, assignment and other provisions in certain agreements to which Innovium is a party. If Innovium is unable to negotiate waivers of or consents under those provisions, the counterparties may exercise their rights and remedies under the agreements, potentially terminating the agreements or seeking monetary damages or other remedies. Even if Innovium is able to negotiate waivers, the counterparties may require a fee for such waivers or seek to renegotiate the agreements on terms less favorable to Marvell or the surviving corporation. Any of the foregoing or similar developments may have an adverse impact on the businesses, financial condition and results of operations of Marvell and the surviving corporation following the completion of the transaction, or the ability of Marvell to successfully integrate the Innovium business.

Marvell may face risks related to the COVID-19 pandemic which could significantly disrupt and adversely impact Marvell’s manufacturing, research and development, operations, sales and financial results.

Marvell’s and Innovium’s businesses have been, and Marvell’s business may be, adversely impacted by the effects of the COVID-19 pandemic. Following the completion of the merger, Marvell’s third-party manufacturers, suppliers, third-party distributors, sub-contractors and customers are expected to be disrupted by worker absenteeism, quarantines and restrictions on their employees’ ability to work; office and factory closures; disruptions to ports and other shipping infrastructure; border closures; and other travel or health-related restrictions. Depending on the magnitude of such effects on Marvell’s manufacturing, assembling and testing activities or the operations of Marvell’s suppliers, third-party distributors or sub-contractors, Marvell’s supply chain, manufacturing and product shipments may be delayed, which could adversely affect Marvell’s business, operations and customer relationships.

In addition to operational and customer impacts, the COVID-19 pandemic has had, and is expected to continue to have, a significant impact on (including an economic downturn in) the economies and financial markets of many countries, which may adversely affect demand for Marvell’s products and adversely impact Marvell’s operating results in both the near and long term. There can be no assurance that any decreases in sales resulting from the COVID-19 pandemic will be offset by increased sales in subsequent periods.

Marvell may experience disruptions to its business operations resulting from work from home, quarantines, self-isolations and restrictions on the ability of Marvell’s employees to perform their jobs, innovate, work together in teams and collaborate, and such disruptions could impact Marvell’s ability to develop and design its products in a timely manner or meet required milestones or customer commitments. These disruptions may also impact Marvell’s ability to win in time sensitive competitive bidding selection processes. In addition, work from home, quarantines, self-isolations, home schooling, continuing macroeconomic related uncertainty or caring for family members may result in heavy psychological, emotional or financial burdens for some of Marvell’s employees, which may impact their productivity and morale and may lead to higher employee absences and higher attrition rates. Marvell may also become subject to claims or lawsuits by employees, customers, suppliers or other parties regarding actions Marvell may take in its operations in response to the COVID-19 pandemic.

Due to uncertainty regarding the severity and duration of the COVID-19 pandemic and related public health measures and macroeconomic impacts, at this time Marvell and Innovium are unable to predict the full impact of the COVID-19 pandemic on Marvell’s business, financial condition, operating results and cash flows. In addition, the impacts of the COVID-19 pandemic will be exacerbated the longer the pandemic continues.

24

Innovium stockholders will have a significantly lower ownership and voting interest in Marvell following the transaction than they currently have in Innovium and will exercise less influence over management.

Based on the consideration payable to holders of Innovium capital stock pursuant to the merger agreement and the number of shares of Marvell common stock outstanding as of August 19, 2021, it is expected that, immediately after completion of the transaction, former Innovium stockholders will own approximately 2% of the outstanding Marvell common stock. Consequently, former Innovium stockholders will have less influence over the management and policies of Marvell than they currently have over the management and policies of Innovium.

The shares of Marvell common stock to be received by Innovium stockholders upon completion of the transaction will have different rights from shares of Innovium capital stock.

Upon completion of the transaction, Innovium stockholders will no longer be stockholders of Innovium, but will instead become stockholders of Marvell, and their rights as Marvell stockholders will be governed by the terms of Marvell’s amended and restated certificate of incorporation (the “Marvell certificate”) and Marvell’s amended and restated bylaws (the “Marvell bylaws”). The terms of the Marvell certificate and the Marvell bylaws are in some respects materially different from the terms of the Innovium certificate and Innovium’s bylaws (the “Innovium bylaws”), which, together with certain investment agreements entered into by Innovium and certain holders of Innovium capital stock, currently govern the rights of Innovium stockholders. For a discussion of the different rights associated with shares of Innovium capital stock and shares of Marvell common stock, see the section entitled “Comparison of Stockholders’ Rights.”

The merger could have an adverse effect on the Marvell and Innovium brands.

The success of Marvell and Innovium is largely dependent upon the ability of Marvell and Innovium to maintain and enhance the value of their brands, their customers’ connection to and perception of the brands, and a positive relationship with customers and suppliers. Brand value, and as a result the businesses and results of operations of Marvell and Innovium, could be damaged if the merger receives negative publicity or if customers or suppliers otherwise come to have a diminished view of the brands as a result of the merger or the common ownership of the existing businesses.

Risks Related to Marvell’s Business

You should read and consider the risk factors specific to Marvell’s business that will also affect the surviving company after the completion of the transaction. These risks are described in Part I, Item 1A of MTGL’s Annual Report on Form 10-K for the fiscal year ended January 30, 2021 and Part II, Item 1A of the Quarterly Reports on Form 10-Q for the fiscal quarters ended May 1, 2021 and July 31, 2021. See the section entitled “Where You Can Find More Information.”

Risks Related to Innovium’s Business

Innovium faces risks related to the COVID-19 pandemic which currently has, and may continue in the future to, significantly disrupt and adversely impact Innovium’s manufacturing, research and development, operations, sales and financial results.

Although many countries have vaccinated large segments of their population, COVID-19 continues to disrupt business activities, trade, and supply chains in many countries, particularly in Asia and India. Innovium expects these impacts to continue for the foreseeable future.

Innovium’s business has been, and will continue to be, adversely impacted by the effects of the COVID-19 pandemic. In addition to global macroeconomic effects, the COVID-19 pandemic and related adverse public health measures have caused disruption to its global operations and sales. Innovium’s third-party manufacturers, suppliers, third-party distributors, sub-contractors and customers have been, and are expected to continue to be,

25

disrupted by worker absenteeism, quarantines and restrictions on their employees’ ability to work; office and factory closures; disruptions to ports and other shipping infrastructure; border closures; and other travel or health-related restrictions. Depending on the magnitude of such effects on Innovium’s manufacturing, assembling, and testing activities or the operations of Innovium’s suppliers, third-party distributors, or sub-contractors, its supply chain, manufacturing and product shipments will be delayed, which could adversely affect Innovium’s business, operations and customer relationships.

In addition to operational and customer impacts, the COVID-19 pandemic has had, and is expected to continue to have, a significant impact on the economies and financial markets of many countries including an economic downturn, which has affected and may in the future affect demand for Innovium’s products and impact its operating results in both the near and long term. There can be no assurance that any decreases in sales resulting from the COVID-19 pandemic will be offset by increased sales in subsequent periods.

In particular, Innovium has experienced, and expects to continue to experience, some disruption to parts of its global semiconductor supply chain, including procuring necessary components and inputs, such as wafers and substrates, in a timely fashion, with suppliers increasing lead times or placing products on allocation and raising prices. Some of the facilities of Innovium’s key suppliers and other service providers were shut down or operated at reduced capacity for extended periods as a result of COVID-19. This resulted in significant logistical challenges and product delays, which could recur in the event of any future closures of, or periods of reduced operations at, Innovium’s facilities or the facilities of its suppliers and providers.

Innovium has had operating losses each year since its inception and its revenue growth may not continue.

Innovium has incurred operating losses each year since its inception and it may not achieve or maintain profitability in the future. Although Innovium’s annual revenue has increased in recent years, there can be no assurances that it will continue to do so. Innovium expects to make significant expenditures related to the development of its products and expansion of its business, including research and development and sales and administrative expenses. Additionally, Innovium may encounter unforeseen difficulties, complications, product delays and other unknown factors that require additional expenditures. As a result of these increased expenditures, Innovium may have to generate and sustain substantially increased revenue to achieve profitability. Innovium’s revenue growth trends in prior periods may not be sustainable. Accordingly, Innovium may not be able to achieve or maintain profitability, and it may continue to incur significant losses in the future.

Innovium faces intense competition and expects competition to increase in the future, which could reduce its revenue and customer base.

The market for Innovium’s products is highly competitive and it expects competition to intensify in the future. This competition could make it more difficult for Innovium to sell its products, and result in increased pricing pressure, reduced profit margins, increased sales and marketing expenses and failure to capture expected market share, any of which would likely seriously harm Innovium’s business, operating results and financial condition.

Innovium expects increased competition from established and emerging companies both domestically and internationally. Many of its current and potential competitors could have longer operating histories, greater name recognition, larger customer bases and significantly greater financial, technical, sales, marketing and other resources than Innovium has. Potential customers may prefer to purchase from their existing suppliers rather than a new supplier regardless of product performance or features. Innovium expects continued competition from incumbents as well as from new entrants into the markets Innovium serves. Innovium’s ability to compete depends on a number of factors, including:

26

In addition, Innovium cannot assure you that existing customers or potential customers will not develop their own products, purchase competitive products or acquire companies that use alternative methods to enable networking in their systems. Any of these competitive threats, alone or in combination with others, could seriously harm Innovium’s business, operating results and financial condition.

Innovium receives a substantial portion of its revenues from a limited number of customers, and the loss of, or a significant reduction in, orders from one or a few of Innovium’s major customers would adversely affect its operations and financial condition.

Innovium receives a substantial portion of its revenues from a limited number of customers and anticipates that it will continue to be dependent on a limited number of customers for a significant portion of its revenues in the immediate future. In some cases, the portion of Innovium’s revenues attributable to certain customers may increase in the future. However, Innovium may not be able to maintain or increase sales to certain of Innovium’s top customers for a variety of reasons, including the following:

In addition, Innovium’s relationships with some customers may also deter other potential customers who compete with these customers from buying its products. To attract new customers or retain existing customers, Innovium may offer certain customers favorable prices on its products. In that event, Innovium’s average selling prices and gross margins would decline. The loss of a key customer, a reduction in sales to any key customer or Innovium’s inability to attract new significant customers could seriously impact Innovium’s revenue and materially and adversely affect its results of operations.

Innovium’s customers may cancel their orders, change production quantities or delay production, and if Innovium fails to forecast demand for its products accurately, it may incur product shortages, delays in product shipments or excess or insufficient product inventory.

Innovium generally does not obtain firm, long-term purchase commitments from its customers. Because production lead times often exceed the amount of time required to fulfill orders, Innovium often must build in advance of orders, relying on an imperfect demand forecast to project volumes and product mix. Its demand forecast accuracy can be adversely affected by a number of factors, including inaccurate forecasting by its customers, changes in market conditions, and demand for its customers’ products. Even after an order is received, Innovium’s customers may cancel these orders or request a decrease in production quantities. Any such cancellation or decrease subjects Innovium to a number of risks, most notably that Innovium’s projected sales will not materialize on schedule or at all, leading to unanticipated revenue shortfalls and excess or obsolete inventory which Innovium may be unable to sell to other customers. Alternatively, if Innovium is unable to project customer requirements accurately, it may not build enough products, which could lead to delays in product shipments and lost sales opportunities in the near term, as well as force its customers to identify alternative sources, which could affect its ongoing relationships with these customers. If Innovium does not timely fulfill customer demands, its customers may cancel their orders and it may be subject to customer claims for cost of replacement. Either underestimating or overestimating demand would lead to insufficient, excess or

27

obsolete inventory, which could harm Innovium’s operating results, cash flow and financial condition, as well as its relationships with its customers.

Innovium expects its operating results to fluctuate.

Innovium expects its revenues and expense levels to vary in the future, making it difficult to predict future operating results. In particular, Innovium experiences variability in demand for its products as its customers manage their product introduction dates and their inventories. Additional factors that could cause Innovium’s results to fluctuate include, among other things:

Unfavorable changes in any of the above factors, many of which are beyond Innovium’s control, could significantly harm Innovium’s business and results of operations.

Innovium’s products must meet exacting specifications, and defects and failures may occur, which may cause customers to return or stop buying its products.

Innovium’s customers generally establish demanding specifications for quality, performance and reliability that Innovium’s products must meet. However, Innovium’s products are highly complex and may contain defects and failures when they are first introduced or as new versions are released. If defects and failures occur in Innovium’s products during the design phase or after, Innovium could experience lost revenues, increased costs, including warranty expense and costs associated with customer support, delays in or cancellations or rescheduling of orders or shipments, product returns or discounts, diversion of management resources or damage to Innovium’s reputation and brand equity, and in some cases consequential damages, any of which would harm its operating results. In addition, delays in Innovium’s ability to fill product orders as a result of quality control issues may negatively impact its relationship with its customers. Innovium cannot assure you that it will have sufficient resources, including any available insurance, to satisfy any asserted claims.

Innovium may have difficulty selling its products if customers do not design its products into their systems, and the nature of the design process requires it to incur expenses prior to recognizing revenues associated with those expenses which may adversely affect its financial results.

Innovium devotes significant time and resources in working with its customers’ system designers to understand their future needs and to provide products that it believes will meet those needs. The bid selection processes can

28

be lengthy. If a customer’s system designer initially chooses a competitor’s product, it becomes significantly more difficult for Innovium to sell its products for use in that system because changing suppliers can involve significant cost, time, effort and risk for its customers. Thus, Innovium’s failure to win a competitive bid can result in its foregoing revenues from a given customer’s product line for the life of that product. In addition, design opportunities may be infrequent or may be delayed. Innovium’s ability to compete in the future will depend, in large part, on its ability to design products to ensure compliance with its customers’ and potential customers’ specifications. Innovium expects to invest significant time and resources and to incur significant expenses to design its products to ensure compliance with relevant specifications.

Innovium often incurs significant expenditures in the development of a new product without any assurance that its customers’ system designers will select its product for use in their applications. Innovium often is required to anticipate which product designs will generate demand in advance of its customers expressly indicating a need for that particular design. Even if its customers’ system designers select its products, a substantial period of time will elapse before Innovium generates revenues related to the significant expenses it has incurred. Additionally, even if system designers use Innovium’s products in their systems, Innovium cannot assure you that these systems will be commercially successful or that Innovium will receive significant revenue from the sales of its products for those systems.

Innovium may be unsuccessful in developing and selling new products or in penetrating new markets.

Innovium operates in a dynamic environment characterized by rapidly changing technologies and industry standards and technological obsolescence. Innovium’s competitiveness and future success depends on its ability to design, develop, manufacture, assemble, test, market and support new products and enhancements in a timely and cost-effective manner. Innovium’s failure to anticipate a shift in technologies, to develop new technologies or to react to changes in existing technologies could materially delay development of new products, which could result in product obsolescence, decreased revenues and a loss of design wins to its competitors. The success of a new product depends on accurate forecasts of long-term market demand and future technological developments, as well as on a variety of specific implementation factors, including:

If Innovium fails to introduce new products that meet the demand of its customers or penetrate new markets that it targets its resources on, Innovium’s revenues will likely decrease over time and its financial condition could suffer.

Some of Innovium’s operations and a significant portion of its customers and contract manufacturers are located outside of the United States, which subjects Innovium to additional risks, including increased complexity and costs of managing international operations and geopolitical instability.

Innovium maintains sales offices and research and development facilities, and it conducts, and expects to continue to conduct, a significant amount of its business with companies that are located outside the United States, particularly in Asia. Even customers of Innovium that are based in the U.S. often use contract manufacturers based in Asia to manufacture their systems, and it is the contract manufacturers that purchase products directly from Innovium. As a result of Innovium’s international focus, Innovium faces numerous challenges, including:

29

As a result of having global operations, the sudden disruption of the supply chain and/or disruption of the manufacture of Innovium’s customers’ products caused by events outside of Innovium’s control could impact its results of operations by impairing its ability to timely and efficiently deliver its products.

Moreover, the international nature of Innovium’s business subjects Innovium to risk associated with the fluctuation of the U.S. dollar versus foreign currencies. Decreases in the value of the U.S. dollar versus currencies in jurisdictions where Innovium has large fixed costs, or where its third-party manufacturers have significant costs, will increase the cost of such operations which could harm its results of operations.

Innovium outsources wafer fabrication, assembly, testing, warehousing and shipping operations to third parties, and relies on these parties to produce and deliver its products according to requested demands in specification, quantity, cost and time.

Innovium relies on third parties for substantially all of its manufacturing operations, including wafer fabrication, assembly, testing, warehousing and shipping. It depends on these parties to supply it with material of a requested quantity in a timely manner that meets Innovium’s standards for yield, cost and manufacturing quality. Any problems with Innovium’s manufacturing supply chain could adversely impact Innovium’s ability to ship its products to its customers on time and in the quantity required, which in turn could cause an unanticipated decline in its sales and possibly damage its customer relationships.

The fabrication of integrated circuits is a complex and technically demanding process. Innovium’s foundries could, from time to time, experience manufacturing defects and reduced manufacturing yields. Poor yields from Innovium’s foundries, or defects, integration issues or other performance problems in its products could cause Innovium significant customer relations and business reputation problems, harm Innovium’s financial results and result in financial or other damages to its customers. Innovium’s customers could also seek damages from Innovium for their losses. A product liability claim brought against Innovium, even if unsuccessful, would likely be time consuming and costly to defend.

In addition, Innovium’s products are manufactured at a limited number of locations in Taiwan. Because of the geographic concentration of third-party foundries, as well as assembly and test subcontractors, Innovium is

30

exposed to the risk that its operations may be disrupted by regional disasters including, for example, earthquakes (particularly in Taiwan and elsewhere in the Pacific Rim close to fault lines), drought, tsunamis or typhoons, or by pandemics or other actual or threatened public health emergencies such as COVID-19, or by political, social or economic instability, including, for example, the continued constraints in the global supply chain in part as a result of COVID-19. In the case of such an event, Innovium’s revenue, cost of goods sold and results of operations would be negatively impacted. If Innovium experiences manufacturing problems at a particular location, it would be required to transfer manufacturing to a backup location or supplier. Converting or transferring manufacturing from a primary location or supplier to a backup fabrication facility could be expensive and a time consuming process. Innovium may not be able to meet customer needs during such a transition, which could delay shipments, cause a production delay or stoppage for its customers, result in a decline in its sales and damage its customer relationships. In addition, the ability of each foundry to provide Innovium with semiconductor devices is limited by its available capacity and existing obligations. Foundry capacity may not be available when Innovium needs it or at reasonable prices.

Any increase in the manufacturing cost of Innovium’s products could reduce its gross margins and operating profit.

The semiconductor business exhibits ongoing competitive pricing pressure from customers and competitors. Accordingly, any increase in the cost of Innovium’s products, whether by adverse purchase price variances or adverse manufacturing cost variances, will reduce its gross margins and operating profit. In addition, some of Innovium’s competitors may be better financed than Innovium is, may have long-term agreements with its main foundries and may induce Innovium’s foundries to reallocate capacity to those customers. This reallocation could impair Innovium’s ability to secure the supply of components that Innovium needs. These and other related factors could impair Innovium’s ability to meet its customers’ needs and have a material and adverse effect on its operating results.

Innovium relies on third-party technologies for the development of Innovium’s products, and Innovium’s inability to use such technologies in the future would harm Innovium’s ability to remain competitive.

Innovium relies on third parties for technologies that are integrated into Innovium’s products. If Innovium is unable to continue to use or license these technologies on reasonable terms, or if these technologies fail to operate properly, Innovium may not be able to secure alternatives in a timely manner and Innovium’s ability to remain competitive would be harmed. In addition, if Innovium is unable to successfully license technology from third parties to develop future products, Innovium may not be able to develop such products in a timely manner or at all.

Innovium’s failure to protect its intellectual property rights adequately could impair Innovium’s ability to compete effectively or to defend itself from litigation, which could harm Innovium’s business, financial condition, and results of operations.

Innovium relies primarily on patent, copyright, trademark and trade secret laws, as well as confidentiality and non-disclosure agreements and other methods, to protect Innovium’s proprietary technologies and know-how. The failure of Innovium’s patents to adequately protect its technology might make it easier for its competitors to offer similar products or technologies. Innovium’s foreign patent protection is generally not as comprehensive as its U.S. patent protection and may not protect its intellectual property in some countries where its products are sold or may be sold in the future. Even if foreign patents are granted, effective enforcement in foreign countries may not be available.

Monitoring unauthorized use and reducing/minimizing the potential misappropriation of Innovium’s intellectual property is difficult and costly. Although Innovium is not aware of any unauthorized use of its intellectual property in the past, it is possible that unauthorized use of its intellectual property may occur without its knowledge. Innovium cannot assure you that the steps it has taken will prevent unauthorized use of its intellectual property. Innovium’s failure to effectively protect its intellectual property could reduce the value of

31

its technology in licensing arrangements or in cross-licensing negotiations, and could harm its business, results of operations and financial condition.

Some of the software used with Innovium’s products, as well as that of some of its customers, may be derived from so-called “open source” software that is generally made available to the public by its authors and/or other third parties. Such open source software is often made available to Innovium under licenses, such as the GNU General Public License, which impose certain obligations on Innovium in the event Innovium was to make available derivative works of the open source software. These obligations may require Innovium to make source code for the derivative works available to the public, and/or license such derivative works under a particular type of license, rather than the forms of license customarily used to protect its intellectual property. In addition, there is little or no legal precedent for interpreting the terms of certain of these open source licenses, including the determination of which works are subject to the terms of such licenses. While Innovium believes it has complied with its obligations under the various applicable licenses for open source software, in the event the copyright holder of any open source software were to successfully establish in court that Innovium had not complied with the terms of a license for a particular work, Innovium could be required to release the source code of that work to the public and/or stop distribution of that work.

Innovium may in the future be subject to intellectual property rights claims, which are extremely costly to defend, could require Innovium to pay significant damages and could limit its ability to use certain technologies.

Innovium may in the future receive notices that claim Innovium has misappropriated or misused other parties’ intellectual property rights, and, to the extent Innovium gains greater visibility, it faces a higher risk of being the subject of intellectual property infringement claims, which is not uncommon with respect to software technologies in particular. There may be third-party intellectual property rights, including issued or pending patents, which cover significant aspects of Innovium’s technologies or business methods. Any intellectual property claims, with or without merit, could be very time-consuming and expensive to settle or litigate and could divert Innovium’s management’s attention and other resources. These claims could also subject Innovium to significant liability for damages, potentially including treble damages if Innovium is found to have willfully infringed patents or copyrights. These claims could also result in Innovium having to stop using technology found to be in violation of a third party’s rights. Innovium might be required to seek a license for the intellectual property, which may not be available on reasonable terms or at all. Even if a license were available, Innovium could be required to pay significant royalties, which would increase its operating expenses. As a result, Innovium may be required to develop alternative non-infringing technology, which could require significant effort and expense. If Innovium cannot license or develop technology for any infringing aspect of its business, Innovium would be forced to limit or stop sales of one or more of its products or product features and may be unable to compete effectively. Any of these results would harm Innovium’s business, operating results and financial condition.

Cybersecurity risks could adversely affect Innovium’s business and disrupt its operations.

Innovium depends heavily on its technology infrastructure and maintains and relies upon certain critical information systems for the effective operation of its business. Innovium routinely collects and stores sensitive data in its information systems, including intellectual property and other proprietary information about its business and that of its customers, suppliers and business partners. These information technology systems are subject to damage or interruption from a number of potential sources, including, but not limited to, natural disasters, destructive or inadequate code, malware, power failures, cyber-attacks, internal malfeasance or other events. Cyber-attacks on Innovium may include viruses and worms, phishing attacks, and denial-of-service attacks. In addition, Innovium may be the target of email scams that attempt to acquire personal information or company assets.

Innovium has implemented processes for systems under its control intended to mitigate risks; however, it can provide no guarantee that those risk mitigation measures will be effective. While, to Innovium’s knowledge, it

32

has not been the subject of a material attempted cyber-attack or breach, given the frequency of cyber-attacks and resulting breaches reported by other businesses and governments, it is likely Innovium will experience one or more breaches of some extent in the future. Innovium has incurred and may in the future incur significant costs in order to implement, maintain and/or update security systems it feels are necessary to protect its information systems, or it may miscalculate the level of investment necessary to protect its systems adequately. Since the techniques used to obtain unauthorized access or to sabotage systems change frequently and are often not recognized until launched against a target, Innovium may be unable to anticipate these techniques or to implement adequate preventive measures.

Innovium’s business also requires it to share confidential information with suppliers and other third parties. Although Innovium takes steps to secure confidential information that is provided to third parties, such measures may not always be effective and data breaches, losses or other unauthorized access to or releases of confidential information may occur and could materially adversely affect Innovium’s reputation, financial condition and operating results and could result in liability or penalties under data privacy laws.

To the extent that any system failure, accident or security breach results in material disruptions or interruptions to Innovium’s operations or the theft, loss or disclosure of, or damage to its data or confidential information, including its intellectual property, Innovium’s reputation, business, results of operations and/or financial condition could be materially adversely affected.

Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information.

In order to protect Innovium’s proprietary technology, processes and methods, Innovium relies in part on confidentiality agreements with its corporate partners, employees, consultants, advisors and others. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover trade secrets and proprietary information, and in these cases Innovium would not be able to assert any trade secret rights against those parties. Costly and time-consuming litigation could be necessary to enforce and determine the scope of Innovium’s proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect Innovium’s competitive business position.

Indemnity provisions in various agreements potentially expose Innovium to substantial liability for intellectual property infringement and other losses.

Innovium’s agreements with certain partners and other parties include indemnification provisions, under which Innovium agrees to indemnify them for losses suffered or incurred as a result of claims of intellectual property infringement and, in some cases, for damages caused by Innovium. The term of these indemnity provisions is generally perpetual after execution of the corresponding agreement. Large indemnity payments could harm Innovium’s business, operating results and financial condition.

If Innovium fails to manage future growth effectively, Innovium’s business could be harmed.

Innovium has experienced, and may continue to experience, significant expansion of its operations. This growth has placed, and will continue to place, a strain on its employees, management systems and other resources. Managing Innovium’s growth will require significant expenditures and allocation of valuable management resources. If Innovium is unable to manage its growth effectively, Innovium may not be able to take advantage of market opportunities or develop new products and Innovium may fail to satisfy customer requirements, maintain product quality, execute its business plan or respond to competitive pressures. Failing to achieve the necessary level of efficiency in its organization as Innovium grows could harm its business, operating results and financial condition.

33

Innovium’s inability to hire or retain key personnel could adversely affect its business, operating results and financial condition.

Innovium depends on the continued contributions of its senior management and other key personnel. All of Innovium’s executive officers and key employees are at-will employees, which means they may terminate their employment relationship with Innovium at any time. The loss of the services of one or more of these individuals could significantly delay or prevent the achievement of Innovium’s development and strategic objectives and could divert other senior management time in searching for their replacements.

Innovium’s future success also depends on its ability to identify, attract and retain highly skilled engineering, managerial, sales, marketing and other personnel. The loss of the services of any of Innovium’s key personnel, the inability to attract or retain qualified personnel, or delays in hiring required personnel, particularly in engineering and sales, may seriously harm Innovium’s business, financial condition and results of operations. Innovium faces intense competition for qualified individuals from numerous other technology companies. In addition, competition for qualified personnel is particularly intense in the San Francisco Bay Area, where Innovium’s headquarters are located. Often, significant amounts of time and resources are required to train technical, sales and other personnel. Qualified individuals are in high demand. Innovium may incur significant costs to attract and retain them, and Innovium may lose new employees to its competitors or other technology companies before Innovium realizes the benefit of its investment in recruiting and training them. Innovium may be unable to attract and retain suitably qualified individuals who are capable of meeting Innovium’s growing technical, operational and managerial requirements, on a timely basis or at all, and Innovium may be required to pay increased compensation in order to do so. If Innovium is unable to attract and retain the qualified personnel it needs to succeed, its business would suffer. Also, to the extent Innovium hires personnel from competitors, Innovium may be subject to allegations that they have been improperly solicited or divulged proprietary or other confidential information.

In the future, Innovium may not be able to secure financing necessary to operate and grow its business as planned, or to make acquisitions.

In the future, Innovium may need to raise additional funds to expand its sales and marketing and research and development efforts or to make acquisitions. Additional equity or debt financing may not be available on favorable terms or at all. If adequate funds are not available on acceptable terms, Innovium may be unable to fund the expansion of its sales and marketing and research and development efforts or take advantage of acquisition or other opportunities, which could seriously harm Innovium’s business and operating results. If Innovium issues debt, the debt holders may have rights to make claims on Innovium’s assets and the terms of any debt could restrict its operations, including its ability to pay dividends on Innovium’s preferred and common stock.

Innovium’s inability to acquire and integrate other businesses, products or technologies could seriously harm Innovium’s competitive position.

In order to remain competitive, Innovium may seek to acquire additional businesses, products or technologies. If Innovium identifies an appropriate acquisition candidate, Innovium may not be successful in negotiating the terms of the acquisition, financing the acquisition, or effectively integrating the acquired business, product or technology into Innovium’s existing business and operations. Innovium may have difficulty incorporating acquired technologies or products with its existing products, and maintaining uniform standards, controls, procedures and policies. Innovium’s due diligence may fail to identify all of the problems, liabilities or other shortcomings or challenges of an acquired business, product or technology, including issues with intellectual property, regulatory compliance practices, revenue recognition or other accounting practices or employee or customer issues. In addition, any acquisitions Innovium is able to complete may not be accretive to earnings and may not result in any synergies or other benefits Innovium had expected to achieve, which could result in substantial write-offs. Further, completing a potential acquisition and integrating an acquired business, products or technologies would significantly divert management time and resources.

34

If Innovium’s estimates or judgments relating to its critical accounting policies prove to be incorrect, Innovium’s operating results could be adversely affected.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Innovium bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. The results of these estimates form the basis for making judgments about the carrying values of assets, liabilities, and equity, and the amount of revenue and expenses that are not readily apparent from other sources. Significant assumptions and estimates used in preparing Innovium’s consolidated financial statements include those related to revenue recognition, accounting for income taxes, fair value of redeemable convertible preferred stock warrant liability, and stock-based compensation expense. Innovium’s operating results may be adversely affected if its assumptions change or if actual circumstances differ from those in its assumptions, which could cause its operating results to fall below the expectations of securities analysts and investors, resulting in a decline in the price of Innovium’s common stock.

Innovium is subject to U.S. foreign investment regulations, which may impose additional burdens on or may limit investment in Innovium by certain foreign investors.

Innovium is subject to U.S. laws that regulate foreign investments in U.S. businesses and foreign-person access to certain technologies developed and produced in the United States. These laws include Section 721 of the Defense Production Act of 1950, as amended by the Foreign Investment Risk Review Modernization Act of 2018, and the regulations at 31 C.F.R. Parts 800 and 802, as amended, administered by the Committee on Foreign Investment in the United States (“CFIUS”). Application of these laws, including as they are implemented through existing and future regulations, may negatively impact Innovium’s business in various ways, including by restricting Innovium’s access to capital and markets; limiting the collaborations Innovium may pursue; increasing Innovium’s costs and the time necessary to obtain regulatory authorizations and ensure compliance; and imposing monetary fines and other penalties if Innovium does not comply.

Certain current or future investors in Innovium may be considered foreign persons under the CFIUS regulations. If CFIUS determines it has jurisdiction over certain transactions, current or potential future investors in Innovium who are considered foreign persons under the CFIUS regulations may be subject to restrictions that could limit or prevent their investment in Innovium.    

Innovium’s proposed acquisition by Marvell is subject to a number of conditions beyond Innovium’s control. Failure to complete the acquisition could materially and adversely affect Innovium’s future business, results of operations and financial condition.

The consummation of the merger is conditioned on the receipt of the approval of Innovium’s stockholders, as well as the satisfaction of other customary closing conditions, including regulatory approvals and performance in all material respects by each party of its obligations under the merger agreement.

Innovium cannot predict whether and when the conditions will be satisfied. If one or more of these conditions is not satisfied, and as a result, Innovium does not complete the merger, or in the event the proposed merger is not completed or is delayed for any other reason, Innovium’s business, results of operations and financial condition may be harmed because:

35

These or other considerations individually or in combination could have a material adverse effect on Innovium’s business, results of operations and financial condition.

The merger agreement contains provisions that could discourage a potential competing acquiror.

The merger agreement contains “exclusivity” provisions that restrict Innovium’s ability to solicit, initiate, consider, knowingly encourage or accept third party proposals for the acquisition of its capital stock or to pursue an unsolicited offer. These provisions could discourage a potential third-party acquiror from considering or proposing an acquisition transaction, even if it were prepared to pay more favorable per share consideration than what would be received in the merger. If the merger agreement is terminated and Innovium determines to seek another business combination, Innovium may not be able to negotiate a transaction with another party on terms and conditions comparable to, or better than, those of the merger.

Innovium’s executive officers and directors have interests in the merger that may be different from, or in addition to, the interests of its stockholders generally.

Innovium’s executive officers and members of its board of directors may be deemed to have interests in the merger that may be different from or in addition to those of its stockholders, generally. These interests may create potential conflicts of interest. Innovium’s board of directors was aware of these potentially differing interests and considered them, among other matters, in evaluating and negotiating the merger agreement and in reaching its decision to approve the merger agreement and the transactions thereunder. These interests relate to or arise from, among other things:

36

As a result of these interests, the executive officers and directors of Innovium might be more likely to support and to vote in favor of the merger proposal than if they did not have these interests. Innovium’s securityholders should consider whether these interests might have influenced these executive officers and directors to support or recommend voting for the proposals related to the merger.

Innovium will incur significant costs in connection with the merger, whether or not it is consummated.

Innovium will incur substantial expenses related to the merger, whether or not it is completed. Payment of these expenses by Innovium as a standalone entity would adversely affect its operating results and financial condition.

Litigation filed against Innovium and Marvell could prevent or delay the completion of the merger or result in the payment of damages following completion of the merger.

Innovium, Marvell, and members of Innovium’s and Marvell’s respective boards of directors may become subject to litigation related to the merger agreement and the merger, including putative stockholder class actions. Among other remedies, the plaintiffs in such matters may seek to enjoin the merger. The results of complex legal proceedings are difficult to predict, and could delay or prevent the merger from being completed in a timely manner. Moreover, litigation could be time consuming and expensive, could divert the attention of Innovium’s and Marvell’s management away from Innovium’s and Marvell’s regular businesses, and, if adversely resolved against either Innovium or Marvell, could have a material adverse effect on Innovium’s or Marvell’s respective financial condition or the condition of the combined company.

37

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This consent solicitation/prospectus, including the information and other documents incorporated by reference into this consent solicitation/prospectus, contains or incorporates by reference or may contain or may incorporate by reference “forward-looking statements” within the meaning of Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”), including without limitation statements regarding the benefits of the merger, the anticipated timing of the merger and the products and markets of Marvell and Innovium. These statements, which involve risks and uncertainties, relate to analyses and other information that are based on forecasts of future results and estimates of amounts not yet determinable and may also relate to future prospects, developments and business strategies. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Forward-looking statements are made based on expectations and beliefs concerning future events affecting Marvell and Innovium and are subject to uncertainties and factors relating to their respective operations and business environment, all of which are difficult to predict and many of which are beyond our control, that could cause our actual results to differ materially from those matters expressed in or implied by these forward-looking statements.

The forward-looking statements involve risks and uncertainties. The ability of either Marvell or Innovium to predict results or actual effects of its plans and strategies is inherently uncertain. Accordingly, actual results may differ materially from those expressed in, or implied by, the forward-looking statements. Some of the factors that may cause actual results or earnings to differ materially from those contemplated by the forward-looking statements include, but are not limited to, those discussed under the section entitled “Risk Factors” of this consent solicitation/prospectus and those discussed in the filings of Marvell that are incorporated herein by reference, including the following:

38

Because these forward-looking statements are subject to assumptions and uncertainties, actual results might differ materially from those expressed or implied by these forward-looking statements. You are cautioned not to place undue reliance on these statements, which speak only as of the date of this consent solicitation/prospectus or the date of any document incorporated by reference into this consent solicitation/prospectus.

All subsequent written and oral forward-looking statements concerning the merger or other matters addressed in this consent solicitation/prospectus and attributable to Marvell or Innovium or any person acting on behalf of either of them are expressly qualified in their entirety by the cautionary notes contained or referred to in this section. Except to the extent required by applicable law or regulation, Marvell and Innovium undertake no obligation to update these forward-looking statements to reflect events or circumstances after the date of this consent solicitation/prospectus. Neither Marvell nor Innovium gives any assurance that either Marvell or Innovium will achieve their respective expectations.

39

SOLICITATION OF WRITTEN CONSENTS

Purpose of the Consent Solicitation; Recommendation of the Innovium Board

The Innovium board is providing this consent solicitation/prospectus to Innovium stockholders. Innovium stockholders are being asked to approve the merger agreement proposal by executing and delivering the written consent furnished with this consent solicitation/prospectus.

After consideration, the Innovium board unanimously approved and declared advisable the merger agreement and the merger, upon the terms and conditions set forth in the merger agreement, and unanimously determined that the merger agreement and the transaction are fair to and in the best interests of Innovium and its stockholders. The Innovium board unanimously recommends that Innovium stockholders approve the merger agreement proposal.

Innovium Stockholders Entitled to Consent

Innovium stockholders of record as of the close of business on August 1, 2021, the record date, will be entitled to execute and deliver a written consent. As of the close of business on the record date, there were 26,889,842 shares of Innovium common stock outstanding and 84,048,880 shares of Innovium preferred stock outstanding, consisting of 8,067,225 shares of Innovium Series A preferred stock, 18,458,679 shares of Innovium Series B preferred stock, 11,664,846 shares of Innovium Series C preferred stock, 11,610,896 shares of Innovium Series D preferred stock, 2,766,250 shares of Innovium Series D2 preferred stock, 7,305,198 shares of Innovium Series E preferred stock and 14,175,786 shares of Innovium Series F preferred stock, in each case entitled to execute and deliver written consents with respect to the merger agreement proposal, and directors and executive officers of Innovium and their affiliates owned and were entitled to consent with respect to 72,450,917 shares of Innovium common stock and Innovium preferred stock, together as a single class and on an as-converted basis (representing approximately 65.31% of such shares outstanding on that date) and 60,498,383 shares of Innovium preferred stock (representing approximately 71.98% of such shares outstanding on that date), consisting of 1,708,472 shares of Innovium Series E preferred stock (representing approximately 23.39% of such shares outstanding on that date), and 8,289,742 shares of Innovium Series F preferred stock (representing approximately 58.48% of such shares outstanding on that date). Innovium has entered into the support agreements with its directors and executive officers obligating them to deliver written consents in favor of the merger agreement proposal.

Only Innovium stockholders of record at the close of business on August 1, 2021, the record date, will be entitled to execute and deliver a written consent. Each holder of Innovium common stock is entitled to one vote for each share of Innovium common stock held as of the record date. Each holder of Innovium preferred stock is entitled to the number of votes equal to the number of shares of Innovium common stock into which the shares of Innovium preferred stock held by such holder could be converted as of the record date. The holders of Innovium preferred stock will vote together as a single class on an as-converted to common stock basis and the holders of Innovium capital stock will vote together as a single class on an as-converted to common stock basis.

Written Consents; Required Written Consents

The approval of the merger agreement proposal requires the affirmative vote or consent of (i) the holders of at least a majority of the outstanding shares of Innovium capital stock (voting as a single class and on an as-converted basis) entitled to vote thereon and (ii) the holders of at least a majority of the outstanding shares of Innovium preferred stock (voting as a single class and on an as-converted basis) entitled to vote thereon (the foregoing clauses (i) and (ii), collectively, the “Innovium stockholder approval”).

Concurrently with the execution of the merger agreement, Marvell and certain stockholders of Innovium (each, a “support stockholder”), representing approximately 65.09% of Innovium capital stock and approximately 71.98% of the outstanding shares of Innovium preferred stock, as of the date of the merger agreement, entered into a support

40

agreement (the “support agreement”) under which they have agreed, promptly (and in any event within one business day) after the registration statement of which this consent solicitation/prospectus forms a part is declared effective by the SEC, to execute and deliver written consents approving the adoption of the merger agreement and related matters with respect to all of their shares of Innovium capital stock entitled to act by written consent with respect thereto. The support stockholders are required to deliver such written consents even if the Innovium board changes its recommendation that Innovium stockholders approve the merger agreement proposal. The execution and delivery of written consents by all of the support stockholders will constitute the Innovium stockholder approval and, therefore, we expect to receive a number of written consents sufficient to satisfy such approval.

As of the close of business on the record date, directors and executive officers of Innovium and their affiliates owned and were entitled to consent with respect to 72,450,917 shares of Innovium common stock and Innovium preferred stock, together as a single class and on an as-converted basis (representing approximately 65.31% of such shares outstanding on that date) and 60,498,383 shares of Innovium preferred stock (representing approximately 71.98% of such shares outstanding on that date). Innovium currently expects that its directors and executive officers will deliver written consents in favor of the merger agreement proposal, although none of them has entered into any agreements obligating him or her to do so, other than Mr. Khemani and Mr. Agarwal, who have entered into support agreements. Certain of our directors are associated with investors who have entered into support agreements.

Submission of Written Consents

You may consent to the merger agreement proposal with respect to your shares of Innovium capital stock by completing, dating and signing the written consent enclosed with this consent solicitation/prospectus and returning it to Innovium by the consent deadline.

If you hold shares of Innovium capital stock as of the record date and you wish to submit your written consent, you must fill out the enclosed written consent, date and sign it, and promptly return it to Innovium. Once you have completed, dated and signed the written consent, you may deliver it to Innovium by emailing a PDF copy to consents@Innovium.com or by mailing your written consent to Innovium, Inc., 6001 America Center Drive, Suite 200, San Jose, CA 95002, Attention: General Counsel, or submitting it through the electronic portal established by SRS.

Innovium has set September 29, 2021 as the target consent deadline. Innovium reserves the right to extend the consent deadline beyond September 29, 2021. Any such extension may be made without notice to Innovium stockholders.

Innovium has not issued physical stock certificates to its stockholders. A letter of transmittal describing the process for the exchange of shares in the merger will be delivered to Innovium stockholders.

Executing Written Consents; Revocation of Written Consents

You may execute a written consent to approve the merger agreement proposal, or disapprove, or abstain from consenting with respect to, the merger agreement proposal (which is equivalent to a vote against such proposal). If you do not return your written consent, it will have the same effect as a vote against the merger agreement proposal. If you are a record holder of shares of Innovium capital stock and you return a signed written consent without indicating your decision on the proposal, you will have given your consent to approve the merger agreement proposal.

Your consent to the proposal may be changed or revoked at any time before the consent deadline; however, such change or revocation is not expected to have any effect, as the delivery of the written consents contemplated by the support agreement will constitute the Innovium stockholder approval at the time of such delivery. If you wish to change or revoke your consent before the consent deadline, you may do so by sending a new written

41

consent with a later date or by delivering a notice of revocation, in either case by emailing a PDF copy to consents@Innovium.com or by mailing your written consent to Innovium, Inc., 6001 America Center Drive, Suite 200, San Jose, CA 95002, Attention: General Counsel, or submitting it through the electronic portal established by SRS.

Due to the obligations of the support stockholders under the support agreement, a failure of any other Innovium stockholder to deliver a written consent, or any change or revocation of a previously delivered written consent by any other Innovium stockholder, is not expected to have any effect on the approval of the proposals.

Solicitation of Written Consents; Expenses

The expense of preparing, printing and delivering these consent solicitation materials is being borne by Innovium. Officers, employees and representatives of Innovium may solicit consents by telephone and personally, in addition to solicitation by mail or email. These persons will receive their regular compensation but no special compensation for soliciting consents.

42

INFORMATION ABOUT THE COMPANIES

Marvell Technology, Inc.

Marvell is a leading supplier of infrastructure semiconductor solutions, spanning the data center core to network edge. Marvell is a fabless semiconductor supplier of high-performance standard and semi-custom products with core strengths in developing and scaling complex System-on-a-Chip architectures integrating analog, mixed-signal and digital signal processing functionality. Leveraging leading intellectual property and deep system-level expertise as well as highly innovative security firmware, Marvell’s solutions are empowering the data economy and enabling communications across 5G, cloud, automotive, industrial and artificial intelligence applications.

We were incorporated in Delaware on October 20, 2020 under the name Maui Holdco, Inc. and changed our name to Marvell Technology, Inc. in connection with the completion by Marvell Technology Group, Ltd. (“MTGL”) of its acquisition of Inphi Corporation (“Inphi”) on April 20, 2021. Upon completion of the acquisition, MTGL and Inphi became our wholly owned subsidiaries. Our registered and mailing address is 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 and our telephone number there is (302) 295-4840.    

Marvell Shares are listed on Nasdaq under the symbol “MRVL.”

Additional information about Marvell and its subsidiaries is included in documents incorporated by reference into this consent solicitation/prospectus. See “Where You Can Find More Information.”

Merger Sub

Ibiza Acquisition Sub, Inc.

1000 N. West Street, Suite 1200

Wilmington, Delaware 19801

(302) 295-4840

Merger Sub is a Delaware corporation and a wholly owned subsidiary of Marvell that was incorporated on July 27, 2021 for the purpose of entering into the merger agreement. At the effective time, Merger Sub will be merged with and into Innovium, with Innovium continuing as the surviving corporation and a wholly owned subsidiary of Marvell.

Innovium

Innovium, Inc.

6001 America Center Drive, Suite 200

San Jose, CA 95002

(234) 567-8901

Innovium is a leading provider of high performance, innovative switching silicon solutions for Cloud and Edge data centers. Innovium’s TERALYNX family delivers software compatible products ranging from 1Tbps to 25.6Tbps with unmatched telemetry, low latency, programmability, and large buffers, and a feature rich architecture that scales to 100Tbps+. Innovium’s products have been selected and validated by market-leading OEM, Cloud, and ODM customers. The company is headquartered in Silicon Valley, California and is backed by leading venture capital firms including Greylock, WRVI, Capricorn, Premji Invest, BlackRock, DFJ Growth, DAG, Qualcomm Ventures, S-Cubed and Redline.

Innovium, Inc. was incorporated in Delaware on December 11, 2014 and is a privately held company.

43

PRINCIPAL STOCKHOLDERS OF INNOVIUM

The following table and the related notes set forth, to the best of Innovium’s knowledge, information on the beneficial ownership of Innovium capital stock as of the close of business on August 26, 2021 by:

The percentage of ownership is based on 26,889,842 shares of Innovium Common Stock outstanding, 18,067,225 shares of Innovium Series A Preferred Stock outstanding, 18,458,679 shares of Innovium Series B Preferred Stock outstanding, 11,664,846 shares of Innovium Series C Preferred Stock outstanding, 11,610,896 shares of Innovium Series D Preferred Stock outstanding, 2,766,250 shares of Innovium Series D2 Preferred Stock outstanding, 7,305,198 shares of Innovium Series E Preferred Stock outstanding and 14,175,786 shares of Innovium Series F Preferred Stock outstanding, in each case as of August 26, 2021.

Except as indicated in the footnotes to the table below, Innovium believes that the stockholders named in the table have sole voting and investment power with respect to all shares of Innovium capital stock shown to be beneficially owned by them, based on information provided to Innovium by such stockholders. Unless otherwise indicated, the address for each stockholder listed is: c/o Innovium, Inc., 6001 America Center Drive, San Jose, California 95002.

44

45

46

47

48

THE TRANSACTION

The following is a description of certain material aspects of the transaction. This description may not contain all of the information that is important to you. Marvell and Innovium encourage you to carefully read this entire consent solicitation/prospectus, including the merger agreement attached to this consent solicitation/prospectus as Annex A, for a more complete understanding of the transaction.

Structure of the Transaction

The merger agreement provides, among other matters, for the acquisition of Innovium pursuant to a merger, on the terms and subject to the conditions in the merger agreement and in accordance with the DGCL. Pursuant to the merger agreement, at the effective time, Merger Sub will be merged with and into Innovium, with Innovium continuing as the surviving corporation in the merger and as a wholly owned subsidiary of Marvell.

Consideration to Innovium Securityholders

Subject to the applicable provisions of the merger agreement, at the effective time, by virtue of the merger and without any action on the part of the parties or holders of any securities of Innovium or any other person, Innovium capital stock will be converted into the right to receive the consideration described under “The Merger Agreement—Consideration; Effect of the Transaction on Capital Stock,” Innovium options and Innovium RSUs will be treated as described under “The Merger Agreement—Treatment of Innovium Equity Awards,” and Innovium warrants will be treated as described under “The Merger Agreement—Treatment of Innovium Warrants.”

Background of the Transaction

The Marvell Board and Marvell’s management team regularly review Marvell’s performance, future growth prospects and overall strategic direction and consider potential opportunities to strengthen Marvell’s businesses and enhance shareholder value. This entails reviewing Marvell’s strategy as a stand-alone company and considering potential opportunities for business combinations, acquisitions and other financial and strategic alternatives.

For a number of years, Rajiv Khemani, Chief Executive Officer of Innovium, and Raghib Hussain, President, Products and Technologies of Marvell, met periodically to discuss their respective businesses. As a result of Marvell’s acquisition of Inphi Corporation in April 2021, Marvell became a holder of approximately 1.2 million shares of Innovium capital stock, consisting of shares of Innovium Series C preferred stock, Innovium Series D preferred stock, Innovium Series E preferred stock and Innovium Series F preferred stock.

Concurrently, in the first quarter of 2021 Innovium started to have conversations with certain late-stage venture capital firms. One such firm (the “Potential Series G Investor”) expressed an interest in investing in Innovium in a potential subsequent round of financing. Certain executives of Innovium started to have regular conversations with representatives from the Potential Series G Investor with respect to the operations of Innovium and the possible terms of such investment.

Between mid-March and early April, 2021, Mr. Khemani spoke on several occasions with Gary Ignatin, Executive Vice President Corporate Development of Marvell, to discuss Innovium’s products, markets and customers and the possibility of a strategic transaction.

On April 1, 2021, Marvell and Innovium entered into a mutual non-disclosure agreement with respect to a potential strategic transaction, and Mr. Khemani spoke with Mr. Hussain regarding the same.

On April 3, 2021, Mr. Khemani and Stuart Krometis, Vice President, World Wide Sales and Business Development of Innovium, met with several members of Marvell’s management team, including Mr. Hussain,

49

Mr. Ignatin and David Matukaitis, Vice President, Corporate Development of Marvell, to discuss Innovium’s products, markets and customers. On April 12, 2021, Mr. Khemani and Phil Mazzara, General Counsel of Innovium, met with several members of Marvell’s management team, including Mr. Ignatin, Mr. Matukaitis, Jean Hu, Chief Financial Officer of Marvell, and Steve Vermillion, Vice President, Finance, of Marvell, to discuss the financial performance of Innovium.

On April 7, 2021, a senior executive of a potential strategic counterparty (“Party A”) inquired with Mr. Khemani about the possibility of a strategic transaction with Innovium involving Party A and invited Mr. Khemani to have further discussions with the Chief Executive Officer of Party A.

Between April 7, 2021 and April 13, 2021, Mr. Khemani had multiple meetings with senior executives of Party A regarding the possibility of a strategic transaction, including a presentation to the Chief Executive Officer of Party A on April 13. During the same period, Lip-Bu Tan, a director of Innovium, also had similar meetings with the Chief Executive Officer of Party A. Later during the week of April 12, 2021, Party A indicated to Mr. Khemani that Party A was not interested in proceeding with a potential strategic transaction.

On April 12, 2021, Mr. Khemani met with Ms. Hu to discuss financial diligence.

Between late April and mid-May, 2021, Mr. Khemani met on several occasions with Mr. Ignatin and/or Mr. Hussain to discuss the possibility of a strategic transaction.

On May 13, 2021, Innovium granted access to the Potential Series G Investor to a virtual data room for diligence related materials.

On May 19, 2021, Mr. Khemani and Matt Murphy, President and Chief Executive Officer of Marvell, had a dinner in which they discussed their respective businesses and the possibility of a potential strategic transaction between Marvell and Innovium.

On May 20, 2021, Marvell provided an initial non-binding offer letter and exclusivity agreement to Innovium and proposed an aggregate purchase price of $850 million, consisting of shares of Marvell common stock, for all the outstanding equity of Innovium and indicated that it would agree to grant an unspecified number of restricted stock units of an agreed value to agreed Innovium employees after completion of a transaction. On May 21, 2021, Mr. Khemani provided feedback to Marvell that Innovium was seeking an aggregate purchase price of $1.5 billion plus the value of Innovium’s cash, and that it proposed that Marvell assume all unvested equity of Innovium in addition to the purchase price. On May 22, 2021, Mr. Ignatin and Mr. Khemani discussed the Innovium proposal. The parties were in agreement that consideration for any transaction would consist of shares of Marvell common stock. On May 25, 2021, Mr. Hussain communicated to Mr. Khemani that Innovium should provide Marvell with a proposal in which Marvell would retain the value of all cash held by Innovium at closing and in which the aggregate purchase price would cover all equity, vested and unvested.

On May 21, 2021, the Innovium board held a special board meeting at which Marvell’s nonbinding offer letter and the potential transaction with Marvell was discussed.

On May 22, 2021, Mr. Tan communicated with the Chief Executive Officer of Party A to confirm whether Party A had an interest in the possibility of a strategic transaction with Innovium. On May 27, 2021, Mr. Tan met with the Chief Financial Officer of Party A regarding the possibility of a strategic transaction. Party A confirmed that it did not intend to explore a strategic transaction with Innovium.

Also on May 27, 2021, Mr. Khemani communicated to Mr. Hussain that Innovium would accept a proposal with an aggregate purchase price of $1.58 billion for all equity of Innovium, vested and unvested, with Marvell retaining the value of all cash held by Innovium. Later on May 27, 2021, Mr. Murphy met with Mr. Tan to discuss the merits of a transaction and the potential equity value of Innovium.

50

On June 1, 2021, Marvell provided an updated non-binding offer letter and exclusivity agreement to Innovium and proposed an aggregate purchase price of $1.0 billion, consisting of shares of Marvell common stock valued at the Marvell VWAP, for all the outstanding equity of Innovium and indicated that it would agree to grant restricted stock units worth up to an agreed value to agreed Innovium employees after completion of a transaction. On June 5, 2021, Mr. Murphy met with Mr. Tan to discuss the merits of a transaction and the proposed offer price. Mr. Tan proposed an aggregate purchase price of $1.2 billion and that Marvell agree to grant restricted stock units worth up to an agreed value to agreed Innovium employees after completion of a transaction. Mr. Murphy indicated that the maximum aggregate purchase price Marvell would consider was $1.1 billion, but indicated some flexibility on the value of post-transaction restricted stock unit awards.

Also on June 1, 2021, Mr. Khemani met with representatives of the Potential Series G Investor to discuss terms of the potential investment. Later in the same day, the Potential Series G Investor provided a non-binding term sheet to Innovium for a potential Series G preferred stock financing (the “Series G term sheet”).

On June 2, 2021, the Innovium board held a regular board meeting at which Innovium’s ongoing strategic process was discussed, including Marvell’s non-binding offer letter and the Series G term sheet.

On June 4, 2021, Mr. Khemani, Sumeet Gagneja, Chief Financial Officer of Innovium, and Mr. Mazzara met with representatives of the Potential Series G Investor to negotiate the Series G term sheet.

On June 8, 2021, Mr. Murphy met with Mr. Tan to discuss the proposed offer, and Mr. Tan proposed that an aggregate purchase price of $1.1 billion for all the outstanding equity of Innovium and that Marvell agree to grant restricted stock units worth up to an agreed range of value to agreed Innovium employees after completion of a transaction. On June 9, 2021, Marvell provided an updated non-binding offer letter and exclusivity agreement to Innovium and proposed an aggregate purchase price of $1.1 billion, consisting of shares of Marvell common stock valued at the Marvell VWAP, for all the outstanding equity of Innovium and indicated that it would agree to grant restricted stock units worth up to an agreed range of value to agreed Innovium employees after completion of a transaction.

Also on June 8, 2021, Mr. Khemani, Sumeet Gagneja, Chief Financial Officer of Innovium, and Mr. Mazzara met with representatives of the Potential Series G Investor to further negotiate the Series G term sheet.

On June 9, 2021, the Potential Series G Investor provided a revised draft of the Series G term sheet to Innovium.

On June 11, 2021, Mr. Ignatin and Mitch Gaynor, Marvell’s Executive Vice President and Chief Administration and Legal Officer, met with Mr. Khemani and Innovium’s outside counsel, Goodwin Procter LLP (“Goodwin”), to discuss some of the terms in the non-binding offer letter.

Also on June 11, 2021, the Innovium board held a special meeting at which the Series G term sheet as well as the Marvell offer letter was discussed and at which the Innovium board agreed that the offer letter represented a bona fide offer to acquire Innovium. A director of Innovium also sent a message to a potential strategic counterparty (“Party B”) to assess whether Party B would be interested in the possibility of a strategic transaction with Innovium.

Between June 12 and June 17, 2021, Innovium sent contractually required notices to six companies, including Party A, notifying each of them that Innovium was engaged in discussions regarding a strategic transaction. These notices resulted in preliminary discussions with the five recipients other than Party A; these five parties did not express interest in the possibility of a strategic transaction with Innovium.

51

In addition, over the course of June 2021, Innovium initiated discussions with four additional companies (Party B as described above, a potential strategic party (“Party C”) as described below, and two additional potential strategic parties) to discuss the possibility of a strategic transaction with Innovium. Other than Party B and Party C as described below, these parties did not express interest in the possibility of a strategic transaction with Innovium.

On June 14, 2021, Mr. Gagneja and Mr. Mazzara met with representatives of the Potential Series G Investor to further negotiate the Series G term sheet.

On June 16, 2021, Party B sent Mr. Khemani a message to initiate discussions regarding a potential strategic transaction with Innovium, including as to potential price ranges.

Following an introduction by a member of the Innovium board to a senior executive at Party C, on June 17, 2021, Mr. Khemani met with representatives of Party C. Later in the day, Party C communicated that they were deciding not to proceed with a potential strategic transaction.

On June 18, 2021, Innovium sent a draft term sheet to Party B for an acquisition of Innovium. On June 18, 2021 and June 21, 2021, Mr. Khemani and Mr. Agarwal met with representatives of Party B to discuss preliminary diligence matters. Later in the day on June 21, 2021, Party B communicated that they were deciding not to proceed with a potential strategic transaction with Innovium.

Between June 11 and June 23, 2021, Marvell and its outside counsel, Gibson, Dunn & Crutcher LLP (“Gibson”) and Innovium and Goodwin met on numerous occasions to negotiate various terms in the non-binding offer letter and exclusivity agreement, and exchanged several drafts of the documents. Pursuant to these negotiations, Innovium requested and Marvell agreed to certain terms including Marvell obtaining a representation and warranty insurance policy and limitation of potential liability of Innovium securityholders for matters covered by such policy, Marvell filing a registration statement on S-4 relating to the transaction and limitation of adjustment of the purchase price for Innovium transaction expenses below $16 million. Pursuant to these negotiations, Innovium requested, but Marvell did not agree to, certain other provisions, including a request to include a collar on the value of Marvell shares to be issued in the merger or calculate the value of the Marvell common stock based on a volume average weighted price prior to closing rather than prior to signing of the merger agreement.

On June 22, 2021, Innovium provided a revised draft of the Series G term sheet to the Potential Series G Investor.

Also on June 22, 2021, the Innovium board held a special board meeting at which Innovium’s ongoing strategic process was discussed, including with respect to the ongoing discussions with Marvell and the Series G term sheet. The Innovium board approved entering into a binding exclusivity letter agreement with Marvell to further explore a strategic transaction consistent with the term set forth in a non-binding letter of intent.

On June 23, 2021, Mr. Khemani met with the Potential Series G Investor to further discuss its interest in an investment in Innovium.

Also on June 23, 2021, Marvell and Innovium entered into a non-binding letter of intent and term sheet. In addition, on June 23, 2021, Marvell and Innovium entered into a binding exclusivity letter agreement that would restrict Innovium from seeking alternative proposals until July 23, 2021, except with respect to the Series G term sheet.

On June 29, 2021, the Innovium board held a regular board meeting at which Innovium’s ongoing strategic process was discussed, including with respect to the ongoing discussions with Marvell and with the Potential Series G Investor.

52

On June 30, 2021, Marvell’s outside legal counsel delivered an initial draft of the merger agreement to Innovium and Goodwin.

Also on June 30, 2021, Goodwin met with outside counsel for the Potential Series G Investor to further discuss its interest in an investment in Innovium.

On July 1, 2021, Innovium granted access to Marvell to a virtual data room for diligence related materials.

Between June 28, 2021 and August 2, 2021, representatives of Innovium and representatives of Marvell, together with their respective outside legal counsel, had numerous meetings and calls to discuss matters relating to due diligence, employee matters and other transaction planning matters.

Between June 30, 2021 and August 1, 2021, representatives of Gibson and representatives of Goodwin exchanged drafts of the merger agreement and ancillary transaction documents, and together with representatives of Marvell and Innovium, held various discussions to negotiate the terms of the merger agreement and other definitive agreements for the transaction. Matters negotiated included the terms of indemnification obligations of Innovium securityholders with respect to covenant breaches, undisclosed transaction expenses and dissenters’ rights claims, required efforts and timing to obtain regulatory approvals, the consequences of failure to obtain regulatory approval and the scope of representations, warranties and covenants. During this time each of Mr. Khemani, Mr. Mazzara and representatives of Goodwin had several discussions with members of the Innovium board regarding the terms of the merger agreement and other definitive agreements.

On July 4, 2021, the Potential Series G Investor provided a revised draft of the Series G term sheet to Innovium.

Throughout July 2021, members of the Innovium board met with various existing co-investors of the Potential Series G Investor to assess the desirability of the Potential Series G Investor as an investor in Innovium.

On July 20 and July 21, 2021, Innovium, Marvell and their respective outside legal counsels met to further negotiate the merger agreement.

On July 23, 2021, the exclusivity agreement expired. Marvell and Innovium and their respective outside counsel continued to negotiate the terms of the merger agreement and ancillary documents and conduct due diligence.

On July 27, 2021, the Innovium board held a special board meeting at which the status of discussions with the Potential Series G Investor as well as Innovium’s negotiations with Marvell and the terms of the merger agreement were discussed.

On July 29, 2021, representatives of Innovium and Goodwin held a reverse due diligence meeting with representatives of Marvell and Gibson.

On August 1, 2021, the Innovium board held a special board meeting at which the terms of the merger agreement were discussed and a status update was provided on the Series G term sheet. Following a review of the merger agreement and of the negotiations between Innovium and its representatives on behalf of Innovium and Marvell and its representatives on behalf of Marvell with respect to the merger agreement, the Innovium board unanimously approved and declared advisable the merger agreement and the transaction, upon the terms and conditions set forth in the merger agreement, and unanimously determined that the merger agreement and the transaction are fair to and in the best interests of Innovium and its stockholders. For a discussion of the factors considered by the Innovium board in approving the merger agreement, see the section entitled “The Transaction—Innovium’s Reasons for the Transaction; Recommendation of the Innovium Board.”

53

On August 2, 2021, the board of directors of Marvell approved entering into the merger agreement.

On August 2, 2021, Marvell and Innovium executed and delivered the merger agreement.

Innovium’s Reasons for the Transaction; Recommendation of Innovium Board of Directors

At a meeting held on August 1, 2021, the Innovium board considered the transaction and the terms of the merger agreement and on August 2, 2021, unanimously approved and declared advisable the merger agreement and the transaction, upon the terms and conditions set forth in the merger agreement, and unanimously determined that the merger agreement and the transaction are fair to and in the best interests of Innovium and its stockholders. The Innovium board unanimously recommends that Innovium stockholders approve each of the proposals by executing and returning the written consent furnished with this consent solicitation/prospectus.

In arriving at this determination and recommendation, the Innovium board, in consultation with Innovium management and Innovium’s legal advisor, engaged in discussions regarding the transaction, received materials for their review and consideration, and considered a variety of factors. The following are some of the significant factors that supported the Innovium board’s decision to approve the merger agreement (which are not in any relative order of importance):

54

In the course of its deliberations, the Innovium board also considered a variety of risks and other potentially negative factors, including the following (which are not in any relative order of importance):

55

56

In addition to considering the factors described above, the Innovium board considered the fact that some of Innovium’s directors and executive officers have other interests in the transaction that may be different from, or in addition to, the interests of Innovium stockholders generally, as more fully described in the section entitled “Interests of Innovium’s Directors and Executive Officers in the Transaction.”

The Innovium board concluded that the risks, uncertainties and potentially negative factors associated with the transaction were outweighed by the potential benefits that it expected Innovium and its stockholders would achieve as a result of entering into the transaction. Accordingly, the Innovium board unanimously approved and declared advisable the merger agreement and the transaction, upon the terms and conditions set forth in the merger agreement, and unanimously determined that the merger agreement and the transaction are fair to and in the best interests of Innovium and its stockholders.

The foregoing discussion of the factors considered by the Innovium board includes the principal positive and negative factors, but is not intended to be exhaustive and may not include all of the factors considered by the Innovium board. In view of the wide variety of factors considered by the Innovium board in connection with its evaluation of the transaction and the complexity of these matters, in reaching its decision to approve the merger agreement and the transaction and to make its recommendation to Innovium stockholders, the Innovium board did not quantify or assign any relative weights to the factors considered, and individual directors may have given different weights to different factors and/or considered other factors altogether. The Innovium board considered each of the applicable factors as a whole in context of the transaction, including thorough discussions with Innovium management and Innovium’s legal advisor, and overall considered such factors to be favorable to, and to support, its determination. It should be noted that this explanation of the reasoning of the Innovium board and certain information presented in this section is forward-looking in nature and, therefore, that information should be read in light of the factors discussed in the sections entitled “Special Note Regarding Forward-Looking Statements” and “Risk Factors.”

In connection with its consideration of the transaction, the Innovium board of directors considered the operating results and financial condition of Innovium. The following sets forth certain summary consolidated financial data of Innovium.

57

Summary Consolidated Financial Data of Innovium

Pursuant to SEC rules, Marvell’s acquisition of Innovium will not require Marvell to file financial information with the SEC on Innovium as a significant subsidiary since none of the financial criteria conditions under SEC Regulation S-X Rule 3-05 will be met at the twenty percent level. Accordingly, Innovium is supplementally providing the following summary consolidated financial data to its securityholders in this consent solicitation/prospectus statement. The summary consolidated financial data for the fiscal year ended January 31, 2021 has been derived from the audited consolidated financial statements of Innovium for the fiscal year ended January 31, 2021, which are not included or incorporated by reference in this consent solicitation/prospectus.

Innovium’s preliminary estimated unaudited revenue for the three months ended April 30, 2021 is $19.0 million, compared to revenue for the three months ended April 30, 2020 of $4.5 million. The estimated revenue for the three months ended April 30, 2021 has not been audited or reviewed by Innovium’s independent auditor or any other independent accountants, is solely based on information available to Innovium as of the date of this consent solicitation/prospectus, is inherently uncertain and subject to change and is not a comprehensive statement of Innovium’s financial results for the three months ended April 30, 2021. In addition, the summary financial data presented herein are not necessarily indicative of the results to be achieved in any future period.

Regulatory Approvals

Under the HSR Act, the merger cannot be completed until, among other things, Marvell and Innovium each files a notification and report form with the U.S. Federal Trade Commission (the “FTC”) and the Antitrust Division of the Department of Justice (the “DOJ”) and the applicable waiting period has been terminated or has expired. A transaction notifiable under the HSR Act may not be completed until the expiration of a 30-day

58

waiting period following the parties’ filings of their respective HSR Act notification and report forms or the early termination of that waiting period. If the FTC or the DOJ issues a request for additional information or documentary material with respect to the transaction (a “second request”) prior to the expiration of the initial waiting period, the parties must observe a second 30-day waiting period, which would begin to run only after both parties have substantially complied with the second request, unless the waiting period is terminated earlier or the parties otherwise agree to extend the waiting period. On August 18, 2021, each of Marvell and Innovium filed a notification and report form pursuant to the HSR Act with the FTC and the DOJ.

In connection with the transaction, the parties also intend to make all required filings with the SEC, the Delaware Secretary of State and Nasdaq, as well as any required filings with state or local licensing authorities.

Listing of Marvell Common Stock

It is a condition to the closing that the shares of Marvell common stock to be issued to Innovium stockholders in the merger have been approved for listing on Nasdaq, subject to official notice of issuance, prior to the closing date. It is expected that, following the transaction, the Marvell common stock will continue to trade on Nasdaq under the ticker symbol “MRVL.”

Support Agreement

Concurrently with the execution of the merger agreement, Marvell and the support stockholders entered into the support agreement. Pursuant to the support agreement, each of the support stockholders has agreed, promptly (and in any event within one business day) after the registration statement of which this consent solicitation/prospectus forms a part is declared effective under the Securities Act by the SEC, to execute

and deliver a written consent approving the adoption of the merger agreement and related matters with respect to all of its shares of Innovium capital stock entitled to act by written consent with respect thereto. The execution and delivery of written consents by all of the support stockholders will constitute the Innovium stockholder approval and, therefore, we expect to receive a number of written consents sufficient to satisfy such approval. See the section entitled “Support Agreement.”

Restrictive Covenant Agreements

Concurrently with the entry into the merger agreement, Marvell entered into restrictive covenant agreements with each of Rajiv Khemani and Puneet Agarwal (the “restrictive covenant agreements”). Pursuant to the restrictive covenant agreements, each of Mr. Khemani and Mr. Agarwal have agreed that, during the period commencing on the closing date and ending on the second anniversary of the closing date (the “restrictive period”), he will not, directly or indirectly engage in competition worldwide, knowingly permit his name directly or indirectly to be used by or to become associated with any person that engages in competition worldwide or induce or assist any other person to engage in competition worldwide. For purposes of the restrictive covenant agreement, competition means developing, designing, researching, delivering, licensing, distributing, offering, marketing, and/or selling, (A) technical support and maintenance related to, or (B) all professional and other services related to, in each case, products or services related to (i) switching integrated circuits, software or systems, and (ii) gearbox and retimer integrated circuits.

In addition, during the restricted period, each of Mr. Khemani and Mr. Agarwal have agreed to limitations on solicitation of employees of Marvell and its subsidiaries (including Innovium from and after the closing date), have agreed not to interfere with customer or supplier relationships of Marvell and its subsidiaries (including Innovium from and after the closing date) and have agreed not to make disparaging statements regarding Marvell or its subsidiaries (including Innovium from and after the closing date).

59

Management Following the Transaction

Upon the completion of the transaction, the directors and executive officers of Marvell will remain unchanged as disclosed in Part III, Item 10 of MTGL’s Annual Report on Form 10-K for the fiscal year ended January  30, 2021.

Accounting Treatment

Marvell and Innovium prepare their financial statements in accordance with GAAP. The merger will be accounted for in accordance with FASB ASC Topic 805, Business Combinations, with Marvell considered as the accounting acquirer and Innovium as the accounting acquiree. Accordingly, Marvell will measure the assets acquired and liabilities assumed at their fair values including net tangible and identifiable intangible assets acquired and liabilities assumed as of the closing date, with any excess purchase price over those fair values being recorded as goodwill.

Tax Treatment of the Merger

The merger is intended to qualify as a “reorganization” within the meaning of Section 368(a) of the Code. In connection with the filing of the registration statement of which this consent solicitation statement/prospectus is a part, Goodwin Procter LLP has delivered an opinion to Innovium the effect that the merger should qualify as a “reorganization” within the meaning of Section 368(a) of the Code. Such opinion will be or is based on, among other things, certain facts, representations and covenants, each made by officers of Marvell and Innovium, and assumptions, all of which must be consistent with the state of facts existing at the time of the merger. If any of these facts, representations, covenants and assumptions are, or become, inaccurate or incomplete, such opinions may be invalid, and the conclusions reached therein could be jeopardized. An opinion of counsel represents counsel’s best legal judgment and is not binding on the IRS or the courts, which may not agree with the conclusions set forth in such opinion.

No ruling has been, or will be, sought by Marvell or Innovium from the IRS with respect to the merger and there can be no assurance that the IRS will not challenge the qualification of the merger as a “reorganization” under Section 368(a) of the Code or that a court would not sustain such a challenge. If the IRS successfully challenges the reorganization status of the merger, U.S. holders (as defined under “U.S. Federal Income Tax Consequences”) will be treated as if they sold their Innovium common stock in a fully taxable transaction.

60

THE MERGER AGREEMENT

The following section summarizes certain material provisions of the merger agreement, which is included in this consent solicitation/prospectus as Annex A and is incorporated by reference herein. The summary of the merger agreement below and elsewhere in this consent solicitation/prospectus is qualified in its entirety by reference to the merger agreement. This summary does not purport to be complete and may not contain all of the information about the merger agreement that is important to you. This section is not intended to provide you with any factual information about Marvell or Innovium. The rights and obligations of Marvell and Innovium are governed by the merger agreement and not by this summary or any other information contained in or incorporated by reference into this consent solicitation/prospectus. Marvell stockholders and Innovium stockholders are urged to read the merger agreement carefully and in its entirety, as well as this consent solicitation/prospectus and the information incorporated by reference into this consent solicitation/prospectus.

Explanatory Note Regarding the Merger Agreement

The merger agreement is attached to this consent solicitation/prospectus as Annex A and described in this summary to provide you with information regarding its terms. The merger agreement contains representations and warranties by Innovium, on the one hand, and by Marvell and Merger Sub, on the other hand, which were made solely for the benefit of the other parties for purposes of the merger agreement. The representations, warranties and covenants made in the merger agreement by Innovium were qualified and subject to important limitations agreed to by Innovium, Marvell and Merger Sub in connection with negotiating the terms of the merger agreement. In particular, in your review of the representations and warranties contained in the merger agreement and described in this summary, it is important to bear in mind that the representations and warranties were negotiated with the principal purpose of allocating risk between the parties to the merger agreement, rather than establishing matters as facts about Innovium or Marvell or any other person at the time they were made or otherwise. The representations and warranties may also be subject to a contractual standard of materiality different from that generally applicable to stockholders and reports and documents filed with the SEC, and some were qualified by the matters contained in the confidential disclosure letters that Innovium delivered in connection with the merger agreement and certain documents Marvell filed with the SEC. Moreover, information concerning the subject matter of the representations and warranties, which do not purport to be accurate as of the date of this consent solicitation/prospectus, may have changed since the date of the merger agreement. Accordingly, the representations and warranties and other provisions of the merger agreement should not be read alone, but instead should be read together with the information provided elsewhere in this consent solicitation/prospectus and in the documents incorporated by reference into this consent solicitation/prospectus. See the section entitled “Where You Can Find More Information.”

The Transaction

The merger agreement provides, among other matters, for the acquisition of Innovium pursuant to a merger, on the terms and subject to the conditions in the merger agreement and in accordance with the DGCL. At the effective time, Merger Sub will be merged with and into Innovium, with Innovium continuing as the surviving corporation in the merger and as a wholly owned subsidiary of Marvell.

At the effective time, the certificate of incorporation of the surviving corporation will be amended to read the same as the certificate of incorporation of Merger Sub as in effect immediately prior to the effective time until thereafter changed or amended. Additionally, at the effective time, the bylaws of the surviving corporation will be amended to read the same as the bylaws of Merger Sub as in effect immediately prior to the effective time until thereafter changed or amended.

The officers and directors of Merger Sub immediately prior to the effective time will be the initial officers and directors of the surviving corporation, until their successors are duly elected or appointed and qualified.

61

Closing; Effective Time

The closing of the merger will take place at 10:00 a.m., Pacific time, on the fifth business day following the satisfaction or, to the extent permitted by applicable Law (as defined in the merger agreement), waiver of all conditions to the obligations of the parties set forth in the merger agreement (other than such conditions as may, by their terms, only be satisfied at the closing or on the closing date), or at such other place or at such other time or on such other date as the parties mutually may agree in writing. Notwithstanding the foregoing, subject to certain provisions regarding Marvell’s waiver of closing conditions, if the closing would otherwise be required to occur during the last 10 business days of any fiscal quarter of Marvell, then Marvell may elect to delay the closing until the second business day of the following fiscal quarter of Marvell. If Marvell elects to delay the closing, Marvell shall concurrently be waiving their closing conditions.

On the closing date, the parties will cause a certificate of merger with respect to the merger to be duly executed and filed with the Secretary of State of the State of Delaware as provided under the DGCL and make any other filings, recordings or publications required to be made under the DGCL in connection with the merger. The merger will become effective at such time as the certificate of merger is duly filed with the Secretary of State of the State of Delaware or at such other time as will be agreed to by Innovium and Marvell and specified in the certificate of merger.

Consideration; Effect of the Transaction on Capital Stock

Subject to the applicable provisions of the merger agreement, at the effective time, by virtue of the merger and without any action on the part of the parties or holders of any securities of Innovium or any other person:

Also at the effective time, (a) each share of Innovium capital stock issued and outstanding immediately prior to the effective time that is owned by Marvell, directly or indirectly, or owned or held in treasury by Innovium will automatically be cancelled without payment of any consideration therefor (collectively, the “cancelled shares”), and (b) each share of common stock, par value $0.001 per share, of Merger Sub issued and outstanding immediately prior to the effective time will automatically be converted into and become one fully paid and nonassessable share of common stock of the surviving corporation (“surviving corporation stock”). The cancelled shares of Innovium held by Marvell, however, will be counted as outstanding for the purposes of determining the number of fully diluted shares and shares of Innovium Series E preferred stock and Innovium Series F preferred stock outstanding as of the effective time.

Treatment of Innovium Equity Awards

At the effective time, Innovium options will be treated as follows:

62

At the effective time, each Innovium RSU will be treated as follows:

Each Innovium option or Innovium RSU not described above shall be cancelled without consideration and shall be of no further force and effect.

See the section titled “The Merger Agreement—Treatment of Innovium Equity Awards.”

Treatment of Innovium Warrants

Subject to the applicable provisions of the merger agreement, at the effective time, by virtue of the merger and without any action on the part of the parties or holders of any securities of Innovium or any other person, each Innovium warrant that is outstanding, unexercised and vested as of immediately prior to the effective time will be cancelled and automatically converted into the right to receive a number of shares of Marvell common stock equal to the product of (x) the amount by which the closing common merger consideration exceeds the per share exercise price of the warrant divided by the Marvell VWAP multiplied by (y) the number of shares of Innovium capital stock as to which such Innovium warrant was exercisable immediately prior to the effective time in accordance with the terms of the applicable Innovium warrant, less applicable tax withholding and other authorized deductions. If an Innovium warrant is exercised prior to the effective time, the shares issued in respect of the warrant will be treated as provided in the merger agreement for the applicable class or series of shares.

63

Any warrants that are unvested as of immediately prior to the effective time will be cancelled without consideration.

Definitions

As used in this consent solicitation/prospectus:

“closing common exchange ratio” means the closing common per share merger consideration divided by the Marvell VWAP.

“closing common merger consideration” means $1.1 billion minus the transaction expense adjustment, if any, and minus (i) the closing Series E merger consideration and (ii) the closing Series F merger consideration.

“closing common per share merger consideration” means the closing common merger consideration divided by the number of shares of Innovium common stock outstanding as of immediately prior to the effective time on a fully diluted basis (other than upon the conversion of Innovium Series E preferred stock and Innovium Series F preferred stock) as determined pursuant to the merger agreement.

“closing Series E exchange ratio” means the closing Series E per share merger consideration divided by the Marvell VWAP.

“closing Series E merger consideration” means approximately $61,999,946 million, which is the closing Series E per share merger consideration multiplied by the number of shares of Innovium Series E preferred stock outstanding immediately prior to the effective time of the merger.

“closing Series E per share merger consideration” means $8.4871 (as adjusted in accordance with the terms of the certificate of incorporation of Innovium for any stock splits, stock dividends, combinations, subdivisions, recapitalizations or the like with respect to the Innovium Series E preferred stock).

“closing Series F exchange ratio” means the closing Series F per share merger consideration divided by the Marvell VWAP.

“closing Series F merger consideration” means approximately $143,643,240 million, which is the closing Series F per share merger consideration multiplied by the number of shares of Innovium Series F preferred stock outstanding immediately prior to the effective time of the merger.

“closing Series F per share merger consideration” means $10.1330 (as adjusted in accordance with the terms of the certificate of incorporation of Innovium for any stock splits, stock dividends, combinations, subdivisions, recapitalizations or the like with respect to the Innovium Series F preferred stock).

“continuing employees” means employees of Innovium employed by Marvell or any of its affiliates immediately after the effective time.

“Marvell VWAP” means the volume weighted average price of a share of Marvell common stock for the 10-trading-day period up to and including the trading day immediately preceding the date of the merger agreement, as reported by Bloomberg, which is $57.7409.

“transaction expense adjustment” means an amount equal to the greater of (x) $0 and (y) the amount of Innovium transaction expenses, as determined pursuant to the merger agreement, minus $16 million.

64

Adjustment to Merger Consideration

In the event of any stock split, reverse stock split, stock dividend (including any dividend or distribution of securities convertible into capital stock), reorganization, reclassification, combination, recapitalization or other like change with respect to the Innovium capital stock or Marvell common stock occurring after the date of the merger agreement and before the effective time, the calculations provided for in the merger agreement shall be equitably adjusted to the extent necessary to provide the parties the same economic effect as contemplated by the merger agreement prior to such stock split, reverse stock split, stock dividend, reorganization, reclassification, combination, recapitalization or other like change.

Exchange Procedures

Prior to the effective time, Marvell will designate the transfer agent for the Marvell common stock, or another person selected by Marvell and reasonably acceptable to Innovium, to act as the exchange agent in connection with the merger (the “exchange agent”). After the Innovium stockholder approval is obtained, a letter of transmittal, the form of which is attached to this consent solicitation/prospectus as Annex C will be delivered to Innovium stockholders, warrant holders (subject to certain exceptions) and holders of Innovium equity awards who are receiving consideration but whose awards are not being assumed by Marvell. Upon receipt by the exchange agent of a validly executed letter of transmittal duly completed in accordance with the instructions provided by the exchange agent and any other documents reasonably required by the exchange agent, after the transaction is completed, (a) the holder of such Innovium capital stock, vested Innovium warrant or Innovium equity awards shall be entitled to receive, and Marvell shall cause the exchange agent to pay to such holder, in exchange therefor, the merger consideration issuable in respect of such Innovium capital stock or vested warrant, and (b) such Innovium capital stock, Innovium warrant or Innovium equity award will be cancelled.

At the effective time, the stock transfer books of Innovium will be closed and thereafter there will be no further registration of transfers of Innovium capital stock or Innovium warrants. Until surrendered, each certificate, each Innovium warrant and each equity grant document will be deemed at any time after the effective time to represent only the right to receive the applicable portion of the aggregate merger consideration payable in respect thereof, any cash amount payable in respect of fractional shares of Marvell common stock and any dividends or other distributions on shares of Marvell common stock payable in accordance with the applicable provisions of the merger agreement.

At any time following the date that is one year after the effective time, Marvell shall be entitled to require the exchange agent to deliver to it any consideration (including any interest or other income received with respect thereto) that had been made available to the exchange agent and that have not been disbursed to Innovium securityholders due to such securityholder not returning a letter of transmittal, and thereafter such holders shall be entitled to look to Marvell only as general creditors thereof with respect to any portion of the merger consideration, without interest; subject to an obligation to use commercially reasonable efforts to contact applicable Innovium securityholders. To the fullest extent permitted by applicable Law, none of the exchange agent, Marvell or the surviving corporation in the merger shall be liable to any Innovium securityholder for any amount properly delivered to a public official pursuant to any applicable abandoned property, escheat or similar law.

No dividends or other distributions with respect to Marvell common stock with a record date after the effective time will be paid to any holder of Innovium capital stock, equity awards or warrants that has not yet returned a letter of transmittal with respect to the Marvell common stock issuable pursuant to the merger agreement, and all such dividends and other distributions will be paid by Marvell to the exchange agent until the delivery of the letter of transmittal. Subject to applicable law, following delivery of a letter of transmittal, there will be paid to the holder thereof, without interest, the amount of dividends or other distributions with a record date after the effective time paid with respect to such shares of Marvell common stock to which such holder is entitled pursuant to the merger agreement.

65

No interest will be paid or will accrue on any portion of the aggregate merger consideration (including any amounts that any holder has the right to receive in respect of dividends or other distributions on shares of Marvell common stock payable in accordance with the applicable provisions of the merger agreement).

No Fractional Shares

Marvell will not issue fractional shares of Marvell common stock in the transaction. Each converting holder who would otherwise have been entitled to receive a fraction of a share of Marvell common stock (after aggregating all shares of Marvell common stock, including fractional shares, that would be issued to such converting holder) will receive one share of Marvell common stock if the aggregate amount of fractional shares of Marvell common stock the applicable holder would otherwise be entitled to is equal to or exceeds 0.50; or (ii) no shares of Marvell if the aggregate amount of fractional shares of Marvell common stock such holder would otherwise be entitled to is less than 0.50.

Withholding Rights

Each of Marvell, Innovium, the surviving corporation and the exchange agent will be entitled to deduct and withhold from amounts otherwise payable pursuant to the merger agreement any amounts as are required to be deducted or withheld with respect to such payment under the Code or any other applicable tax law. To the extent that amounts are so deducted or withheld, such amounts will be treated as having been paid to the person in respect of which such deduction or withholding was made and paid over to the proper governmental entity.

Dissenting Shares

Any share of Innovium capital stock, as of the effective time, held by a holder who is entitled to demand and has properly demanded appraisal for such shares under Section 262 of the DGCL (a “dissenting share”) will not be converted into or represent a right to receive the consideration set forth in the applicable provisions of the merger agreement, unless and until such holder fails to perfect or withdraws or otherwise loses his right to appraisal and payment under the DGCL. If, after the effective time, any such holder fails to perfect or withdraws or loses such holder’s right to appraisal, such dissenting shares will be treated as if they had been converted as of the effective time into the right to receive the portion of the merger consideration, if any, to which such holder is entitled pursuant to the merger agreement, without interest. For information about the procedure for exercising appraisal rights, see the section entitled “Appraisal Rights.”

Representations and Warranties

The merger agreement contains representations and warranties by Innovium, Marvell and Merger Sub that are subject to certain exceptions and qualifications (including exceptions and qualifications related to knowledge, materiality and material adverse effect).

The merger agreement contains representations and warranties by Innovium relating to, among other things, the following:

66

The merger agreement includes a more limited set of representations and warranties by Marvell and Merger Sub relating to, among other things, the following:

Many of the representations and warranties in the merger agreement are qualified by a “materiality” or “material adverse effect” standard (that is, they will not be deemed to be untrue or incorrect unless their failure to be true or correct would be material to, or have a material adverse effect on, the applicable party).

67

For purposes of the merger agreement, a “material adverse effect” means, with respect to any person, including Innovium or Marvell, any event, change, circumstance, occurrence, effect or result that, individually or in the aggregate, (i) is or would reasonably be expected to be materially adverse to the business, assets, financial condition or results of operations of such person and its subsidiaries, taken as a whole, or (ii) materially impairs the ability of such person to consummate, or prevents or materially delays, the merger or would reasonably be expected to do so. However, with respect to clause (i), a material adverse effect shall not include any event, change, circumstance, occurrence, effect or result to the extent resulting from:

provided that, with respect to the second, third and fourth bullets above, the impact of such event, change, circumstances, occurrence, effect or result is not disproportionately adverse to such person and its subsidiaries, taken as a whole, as compared to other similarly situated companies.

Covenants and Agreements

Conduct of Business of Innovium Prior to Completion of the Transaction

Innovium has agreed that, between the date of the merger agreement and the effective time, except as set forth in the Innovium disclosure schedule, as required or expressly permitted by the merger agreement, as required by applicable law or as consented to in writing by Marvell (which consent will not be unreasonably withheld, conditioned or delayed, except in certain specified cases), Innovium (a) will, and will cause each Innovium subsidiary to, use its commercially reasonable efforts to (i) preserve substantially intact the business organization and assets of Innovium and its subsidiaries; (ii) preserve in all material respects the current relationships of Innovium and its subsidiaries with customers, suppliers and other persons with which Innovium or any of its subsidiaries has significant business relations; (iii) keep and maintain in all material respects the assets and properties of Innovium and its subsidiaries in good repair and normal operating condition, wear and tear excepted, (iv) place orders with suppliers for die bank that is reasonable based on supply available and

68

allocations of that supply to Innovium, and (v) continue to enter into commercial transactions consistent with the ordinary course of business; and (b) will not, and will cause each Innovium subsidiary not to: